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ABSTRACT 
Salinomycin, a widely used anti-coccidial agent, was recently identified as a cancer stem 
cell (CSC) inhibitor from a library of 16,000 natural and commercial chemical compounds based 
on its highly selective inhibitory effect on breast CSCs, with more than 100-fold greater potency 
than paclitaxel. Salinomycin also exhibits cytotoxic effects on other types of cancer cells and 
CSCs and overcomes drug resistance. However, the exact mechanism of salinomycin, especially 
its direct binding target(s), and its effects on Neuroblastoma (NB) are yet not known.  
NB is a common solid tumor and a leading cause of mortality in children. Currently, 35% 
of patients with NB remain incurable. In addition, the majority survivors of NB suffer from long-
term side effects of current therapies and are at risk for disease relapse or getting a second, 
different cancer. More effective therapies are pressingly needed. Since the existence of CSCs in 
human NB cell lines and NB tumors has been well documented, and has been closely associated 
with chemoresistance or tumor relapse, therapeutic targeting of NB CSCs may be a critical novel 
approach for NB therapy. 
Aiming to improve NB therapy, we examined the efficacy and mechanism of 
salinomycin in human NB cells. Our study showed that salinomycin markedly inhibits NB cell 
proliferation and tumorsphere formation. Treatment of salinomycin induced G2 cell cycle arrest 
with an up-regulation of Cyclin A and a down-regulation of p21 protein levels. We further 
identified Transcription intermediary factor 1-beta (TIF1β) and Nucleolin (NCL) as novel 
binding targets of salinomycin by using comprehensive methods, including chemical proteomics 
and functional genomics. We demonstrate that salinomycin induced phosphor-TIF1β mediated 
down-regulation of p53 and significantly suppressed the expression of CD34, a CSC marker, via 
disrupting the interaction of NCL with the CD34 promoter. Furthermore, by analyzing tumor 
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samples data from a cohort of 498 NB patients, we found that elevated levels of TIF1β and NCL 
in NB are associated with a poor outcome. These results provide a therapeutic rationale for 
evaluating of both salinomycin and its binding proteins, TIF1β and NCL, in NB.  
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CHAPTER 1. INTRODUCTION 
1.1. Neuroblastoma (NB) 
NB is a tumor derived from primitive neural crest cells of the sympathetic nervous 
system and is the most common extracranial solid tumor diagnosed in children as well as a 
predominant tumor in infants [1]. Each year, approximately 700 new cases are diagnosed in the 
United States [2]. This disease usually affects children under the age of five and can occur even 
before a child is born [2]. NB tumor most frequently originates in one of the adrenal glands, but 
can also develop in nerve tissues of other sides, such as neck, chest, abdomen, or pelvis (Figure 
1). Unfortunately, at the time of diagnosis, in 50-70% of these cases, the disease has already 
metastasized [1].  
 
Figure 1. Primary distribution of NB in children (Illustration courtesy of the American 
Society of Clinical Oncology). 
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Recent advances in understanding the biology, pathology, and genetics of NB have 
allowed the classification of NB as low-, intermediate-, and high-risk groups. Although the 
outcomes for patients with low- or intermediate-NB are usually favorable, less than 40% of the 
children with high-risk NB respond to current available therapies [3, 4]. In addition, survivors of 
intermediate to high-risk NB often experience severe side effects caused by therapies currently in 
use, including hearing loss, alterations in growth and development, learning difficulties and 
greater risk of secondary cancers and disease relapse [1, 5, 6]. Thus, more effective and less 
harmful treatment strategies are pressingly needed. 
 
1.1.1. Signs and symptoms of NB 
Fatigue, loss of appetite, irritability, fever, and joint pain are common first symptoms of 
NB [1, 7, 8]. Since these symptoms can also be caused by medical conditions and diseases other 
than cancer, these vague signs make the early diagnosis of NB difficult. Along with the tumor 
growth, symptoms will be developed depend on the primary tumor locations and metastasis if 
present (Table 1).  
 
1.1.2. Etiology and risk factors of NB 
The etiology of NB is not well understood. The vast majority of NB cases are sporadic 
and non-familial. A small subset (~1-2%) of NB patients inherits a genetic predisposition to NB, 
such predisposition locus has been mapped at the short arm of chromosome 16 [9]. Rare 
germline mutations in the anaplastic lymphoma kinase (ALK) gene [10], paired mesoderm 
homeobox protein 2B (PHOX2B) gene [11], and kinesin-like protein 1B (KIF1B) gene have been 
implicated in familial NB [12]. 
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Table 1. Symptoms of NB 
Tumor location/ Tumor affecting organs Major symptoms 
Abdomen Swollen belly; Constipation 
Chest Breathing problems 
Spinal cord Weakness; Inability to stand, crawl, or walk 
Bone Pain; Limping 
Bone around the eyes or orbits Distinct bruising and swelling 
Bone marrow Pallor from anemia; Bruising 
Skin 
Skin lesions or nodules under the skin with 
blue or purple patches 
Eyes 
Eyes bulge out; Dark circles under the eyes; 
Pupil constricted 
Back Weakness; Numbness; Paralysis of the legs 
Hormone Constant diarrhea; High blood pressure 
Muscle Sudden muscle jerks 
 
The lifestyle-related risk factors playing major roles in many adult cancers, such as body 
weight, physical activity, diet, and tobacco use, were not found to play much of a role in NB as 
well as many other childhood cancers. In addition, no apparent environmental factor has been 
correlated with the incidence of NB. However, the incidence rates of NB are age dependent. The 
age of patients at diagnosis is mostly under 5 years old, and it is very rare in people over 10 years 
old [1, 13, 14]. 
 
1.1.3. Biological features of NB 
Several molecular and cytogenetic features have been implicated in the pathogenesis and 
clinical prognosis of NB. For instance, near-triploidy DNA content has been associated with 
favorable outcome [15, 16], while MYCN oncogene amplification has been predominantly linked 
with more aggressive tumors [15, 17]. Besides the amplification of chromosome 2p24 locus 
where the MYCN gene located, trisomy for the long arm of chromosome 17 (17q) has been found 
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to occur in more than half of all NBs, and such gain of 17q is also associated with more 
aggressive NB [15, 18]. In addition, deletion of the short arm of chromosome 1 (1p) has been 
identified in 70-80% of the near-diploid tumors and is highly associated with MYCN 
amplification [15, 19]. The most common chromosome deletion detected so far is the allelic loss 
of chromosome 11q, which was found in 43% of NB patients [20, 21]. Interestingly, this 
abnormality was implicated with lower event-free survival only in non-MYCN amplification 
patients with unknown reason [21]. Several abnormally expressed genes were also implicated in 
NB. For example, high levels of Tropomyosin receptor kinase A (TrkA) and TrkC gene 
expressions are highly correlated with favorable outcome, while its combination with MYCN 
amplification provides improved prognostic power [22]. Similarly, expression of the 
transmembrane receptor p75 has also been linked with favorable outcome [23]. In contrast, 
expression of full-length TrkB is strongly associated with MYCN amplification and is frequently 
observed in very aggressive NB tumors [24, 25], while truncated TrkB is usually found 
predominantly in more differentiated and lower-staged NB tumors [26].  
 
1.1.4. NB staging and risk groups 
On the basis of the anatomical presence of NB at diagnosis, the “International 
Neuroblastoma Staging System (INSS)” was established in 1986 and last revised on 1993 [27]. 
The criteria for different stages, from stage 1 to stage 4 special (4S), are shown in the following 
table (Table 2). 
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Table 2. International Neuroblastoma Staging System 
Stages Description 
Stage 1 (21%) 
Localized tumor confined to the area of origin. Tumor can 
be completely removed by surgery. Representative 
ipsilateral lymph nodes negative for tumor 
microscopically. 
Stage 2 
(15%) 
Stage 2A 
Localized tumor with incomplete gross resection. 
Representative ipsilateral non-adherent lymph nodes 
negative for tumor microscopically. 
Stage 2B 
Localized tumor with/without complete gross resection. 
Representative ipsilateral lymph nodes positive for tumor 
microscopically. Identifiable contralateral lymph node 
negative for tumor microscopically. 
Stage 3 (17%) 
Un-resectable tumor infiltrating across midline 
with/without regional lymph node involvement; or 
localized tumor with contralateral region lymph node 
involvement; or midline tumor with bilateral lymph node 
involvement. 
Stage 4 (41%) 
Tumor disseminated to distant lymph nodes, bone, bone 
marrow, liver, or other organs except as defined by Stage 
4S. 
Stage 4S (6%) 
Infant (Age <1 year old) with localized primary tumor 
with dissemination limited to skin, liver, or bone marrow. 
 
Due to certain technical limitations of INSS criteria and the significantly advanced 
understanding of NB biology, especially the identification of the MYCN amplification and the 
application of recombinant DNA technology to screen chromosomal deletion, International 
Neuroblastoma Risk Group (INRG) project proposed a new pretreatment staging system uses 
established biological factors to predict how well treatment will work in the year 2009 [28]. 
Current risk stratification is designed on the basis of the new INRG Staging System (INRGSS), 
patient age, tumor grade, histopathology, DNA ploidy, as well as biochemical markers. The risk 
classification system of INRG and its associated molecular factors are shown in Table 3 [29]. 
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Table 3. Biological factors and INRG risk groups 
Parameters Low risk Intermediate risk High risk 
MYCN Normal Normal Amplified 
Age Usually < 1 year Usually > 1 year Usually >1 year 
Stage 1, 2, 4S 2, 3, 4, 4S 2, 3, 4, 4S 
DNA ploidy 
Hyperdiploid, 
Near-triploid 
Near-diploid, Near-
tetraploid 
Near-diploid, Near-
tetraploid 
17q gain Rare Common Common 
11q, 14q LOH Rare Common Rare 
1p LOH Rare Uncommon Common 
TrkA expression High Low or absent Low or absent 
TrkB expression Truncated Low or absent High 
TrkC expression High Low or absent Low or absent 
5-year survival rate 95% 90% to 95% 40% to 50% 
Abbreviation: Loss of heterozygosity (LOH) 
 
1.1.5. Current therapies of NB and outcomes 
Risk based therapy is currently a hallmark of NB treatment. Patients with low risk NB 
may be cured by receiving surgery or chemotherapy alone, or even without any treatment [30]. 
Intermediate risk NB patients often receive chemotherapy before definitive resection. The 
amount and duration of chemotherapy is tailored based on the tumor biological risk factors and 
clinical parameters, as well as the patient’s response to therapy [31]. Since some patients in 
recent studies have been observed successful resection without chemotherapy, to reduce the use 
of chemotherapy is a current trend to minimize side effects [32]. However, for patients with 
symptomatic life-threatening or organ-threatening tumor that does not respond to surgery and 
chemotherapy efficiently, radiation therapy will be applied [33].  
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Therapeutic strategies are much more complex for patients with high risk NB, which 
requires very intensive approaches and several types of treatments. Treatment is generally 
divided into three phases. During the “Introduction phase”, dose-intensive cycles of 
chemotherapeutic drugs, such as cisplatin and etoposide alternating with vincristine, 
cyclophosphamide, and doxorubicin will be used, and the surgical resection of the primary tumor 
will be attempted after the response to chemotherapy [34]. The second phase is the 
“Consolidation phase”, which involves myeloablative chemotherapy and hematopoietic stem cell 
rescue/transplantation (HSCT) and radiation therapy to the site of the primary tumor [34, 35]. 
However, the optimal dose of radiation therapy has not been determined. The “Maintenance 
phase” is the final phase to treat the potential minimal residual disease after the first two phases. 
Patients are usually treated with differentiating agent isotretinoin post HSCT for 6 months along 
with immunotherapy, such as using chimeric anti-GD2 antibody ch14.18 combined with 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 [34-36]. 
Unfortunately, even with these intensive therapeutic approaches, the outcome for high risk NB is 
still unsatisfactory and the survivors of intermediate to high-risk NB often have to experience 
severe side effects.  
The unsatisfactory clinical outcomes of NB underscore the need for the development of 
new treatments with novel action mechanisms. Recently, a stem cell like population in NB, 
namely NB cancer stem cells (NB-CSCs), has been linked with higher potential for treatment 
resistance and disease relapse [37-39]. CSCs in NB thus appear as attractive targets for novel 
therapeutics. 
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1.2. CSC therapy 
CSCs are distinct rare cell populations identified in many cancers with the unique 
features including self-renewal and immortal [40]. Aberrant regulation of gene expression and 
some signaling pathways has been observed in CSCs [41]. Due to the close relationship of CSCs 
with cancer initiation, progression, metastasis, drug resistance, as well as cancer recurrence [41, 
42], CSC-targeted therapeutic strategies are considered as a new promising direction for 
eradicating malignancies. 
 
1.2.1. CSC theory: definition and experimental identification 
CSCs are defined as cells within the tumor that capable of self-renewal and generating 
the heterogeneous lineages of cancer cells that comprise the tumor. One of the important early 
observations led to the CSC theory was that despite most tumors arise from a single cell; cells 
within a tumor are not identical. This phenomenon is also known as tumor heterogeneity, which 
supports the hypothesis that a small fraction of cells- the pluripotent CSCs- can generate bulk 
tumor cells with different phenotypes, which leads to the emergence and growth of tumor. The 
first conclusive experimental evidence was reported by Bonnet and Dick at 1997 on Nature 
Medicine showing that a subpopulation of CD34
+
 CD38
−
 acute myeloid leukemia (AML) cells 
possess the capacities of self-renewal, differentiation, and proliferation and are able to 
reconstitute a heterogeneous tumor in NOD/SCID immune-deficient mice [43]. The first 
discovery of CSCs in solid tumor was followed in 2003 in human brain gliomas by isolating the 
clonogenic and sphere-forming CSCs [44]. With the advances in CSC biology and animal 
models, as well as the improvement on detecting technologies, currently, the CSC theory has 
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gained validation in many kinds of cancers, such as cancers in the breast, pancreas, prostate, 
head and neck, colon, liver, bladder and lung [41]. 
 
1.2.2. Clinical implications of CSCs 
Current clinical treatment regimens shrink the bulk tumor cells but often fail to eradicate 
the CSCs, which might result in drug resistance and tumor recurrence. Thus, CSC theory 
provides a potential for the discovery and development of CSC-oriented therapies which may 
conquer the chemo- or radio-therapy resistant or refractory tumor (Figure 2).  
 
Figure 2. Comparison between CSC therapy and conventional therapy. 
 
Over the past several years, a tremendous amount of efforts has been invested on 
developing CSC targeting therapy. To achieve more accurate CSC targeting and less side effect, 
one of the hot directions is to selectively target the CSC surface markers, such as CD44 [45], 
CD90 [46], CD133 [44] and CD33 [47]. For example, humanized anti-CD33 mouse monoclonal 
antibody conjugated with cytotoxic agent has been developed to be widely used in AML 
treatment [48, 49]. Critical signaling elements and pathways specifically involved in CSCs are 
also common targets for CSC therapy research, with the Notch, Wnt, Hedgehog, and NFκB 
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pathways most heavily studies and the inhibitions of these pathways have shown alluring 
potential to inhibit systemic metastases in vitro and in vivo [50]. ATP-driven efflux transporters 
are commonly up-regulated in CSCs [42]. Several molecular drugs inhibiting ABC cassette are 
currently under clinical trials and showed promising results. For instance, MS-209 have been 
found to overcome drug resistance in breast cancer and other cancers (ClinicalTrials.gov 
Identifier: NCT00004886) and the combination of the ABC inhibitor tariquidar with docetaxel, 
etoposide, mitotane, and vincristine plus surgery in treating patients with primary, recurrent, and 
metastatic adrenocortical cancer is now under phase II clinical trial investigation (Clinical-
Trials.gov identifier: NCT00073996).  Increasing evidence has suggested that therapeutic 
targeting CSCs may lead to improvement and even evolution of cancer treatment. 
 
1.2.3. CSCs in human NB 
During normal development, neural crest stem cells undergo differentiation in the process 
of embryogenesis to form the adrenal medulla and sympathetic ganglia. The failure of such 
proper differentiation leads to NB, which may develop in adrenal medulla and anywhere in the 
sympathetic nervous system [51].  Analyzing NB cells for lineage markers revealed that NB cells 
are of an immature neuroblastic phenotype which are characterized by weak expression of 
neuronal markers such as GAP-43, HNK-1, NPY, and chromogranin A & B [52, 53]. In addition, 
many NB cell lines contain a subset of cells harboring stem cell markers such as CD133, CD34, 
c-kit and nestin [37, 38, 54, 55].  Based on the phenotypes, NB cells are of heterogeneity origin 
[38, 52, 54, 55]. Recent study indicates that the major cause of therapy resistance or relapse is 
due to the existence of CSCs [39]. Indeed, it has been further demonstrated that a subset of NB 
cells  expressing the stem cell marker proteins, such as CD133 and c-Kit, are highly tumorigenic 
and have more potential to develop therapy resistance [37, 38, 56]. Current conventional 
 11 
 
therapies including chemotherapy, radiotherapy and immunotherapy may kill the large 
population of tumor cells but potentially leave behind the CSCs. Since the existence of CSCs in 
human NB cell lines and NB tumors from patients has been well documented by previous studies 
[1, 37, 39], therapeutic targeting of NB CSCs may be a critical novel approach to conquer the 
challenges in the treatment of NB. To this end, understanding the mechanism of the CSC 
targeting drugs and identifying their molecular targets may improve the understanding and 
treatment of NB.  
 
1.3. Salinomycin 
Salinomycin, traditionally used as an anticoccidial drug, has recently been shown to 
possess anti-cancer and anti-CSC activities and also to overcome multi-drug resistance in 
numerous studies using human cancer cell lines and xenograft mice as well as in clinical pilot 
studies in cancer patients. Therefore, salinomycin may be considered as a promising novel anti-
cancer agent despite its largely unknown mechanism of action.  
 
1.3.1. Salinomycin as a coccidiostat 
Salinomycin (molecular formulae, C42H70O11) is a monocarboxylic polyether antibiotic 
isolated from Streptomyces albus strain (Stain No. 80614) (Figure 3). The usage of salinomycin 
in veterinary medicine can be traced back to 1980s [57] as a broad spectrum antimicrobial agent 
with activity against gram-positive bacteria, fungi, and parasites [57-59]. Today, salinomycin is 
one of the most widely used coccidiostats in poultry in the United States [59-63].  
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Figure 3. Structure of salinomycin. 
 
As an antimicrobial drug, salinomycin primarily functions as an ionophore that facilitate 
the transport of cations (K
+
, Na
+
, Ca
+
 or Mg
2+
) through cell membranes of the target organisms 
including protozoa and gram-positive bacteria. Most notably, such facilitated transport increases 
intracellular calcium to levels toxic to coccidians, by inducing the selective disposition of 
osmoregulatory organelles in the cell thereby disrupting the osmotic balance and resulting in 
eventual demise of the responsive organisms [64, 65]. However, such ionophoric properties and 
mechanisms are unlikely to suffice or even applicable for explaining the observed specificity of 
salinomycin on CSCs and multidrug resistant cancer cells. Indeed, several studies have shown 
that salinomycin activates unconventional pathways of cell death, increases DNA damage, and 
inhibits Wnt signaling pathway, all of which purportedly have been linked to anti-cancer 
activities of salinomycin in various types of cancers [66-72]. 
 
1.3.2. Pharmacokinetics and pharmacodynamics of salinomycin 
The pharmacokinetic parameters of salinomycin as an antimicrobial and anticoccidial 
antibiotic have been extensively studied in many animal species. By virtue of its lipid solubility, 
it is readily and rapidly absorbed in the gastro-intestinal tract and distribute throughout the serum 
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and tissues. In respect to tissue distribution, fat tissues showed the highest affinity for 
salinomycin followed by liver and muscle tissues in chicken [73]. Salinomycin is able to 
penetrate blood brain barrier, though the existence of P-glycoprotein could limit its oral 
availability and brain penetration [74]. Liver is the primary metabolism site for salinomycin and 
its rapid metabolism of salinomycin yields a spectrum of numerous metabolites [75]. The 
elimination of salinomycin is moderately fast. It has been suggested that 24 hours should be an 
adequate withdrawal period for salinomycin in chickens [73]. The oral LD50 values of 
salinomycin in broiler chickens and laying hens were 108 and 104 mg/kg body weight 
respectively [76], while the reported LD50 value of salinomycin in horse is only 0.6 μg/kg [77, 
78].   
In a recent reported case study, a patient with advanced and metastatic squamous cell 
carcinoma of the vulva received intravenous administration of 200-250 µg/kg  salinomycin every 
second day combined with other chemotherapeutic drugs such as erlotinib showed favorable 
clinical effects [79]. Though the pharmacokinetic parameters of salinomycin as an anticoccoidal 
agent have been established and may provide insights on pharmacokinetic/pharmacodynamic 
studies of salinomycin in CSCs and human cancer cells, the pharmacokinetic/pharmacodynamic 
studies of salinomycin in CSCs and human cancer cells are still not clear and deserve further 
investigation.   
 
1.3.3. Identification of salinomycin as CSC inhibitor 
Accumulating evidence shows that the presence of CSC is the major cause of cancer 
recurrence after therapy, attributable to CSCs’ self-renewal and tumor initiating capability which 
can repopulate the tumor mass and consequently resist to therapy [40, 41, 80, 81]. Moreover, in 
clinical studies, CSCs also present significant challenge owing to their unique endowment with 
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an enhanced DNA repair system, up-regulation of drug efflux pumps and robust expression of 
anti-apoptotic proteins [39, 42, 82, 83]. Therefore, eradication of CSCs may be considered as a 
key to the circumvention of cancer relapse and chemo-resistance, the major obstacles in current 
cancer therapy. Whereas the epithelial-mesenchymal transition (EMT) has long been recognized 
as a key feature of cancer invasion and metastasis [84-86], Mani et al. (2008) showed that the 
induction of EMT in both human mammary epithelial cells (HMLEs) and mammary carcinomas 
is accompanied by the enrichment of cells with epithelial stem cell properties [87]. Subsequently, 
Gupta et al. showed that EMT transformation of HMLER breast cancer cells (human mammary 
epithelial cells overexpressing hTERT, SV40 T/t and H-RasV12) resulted in the appearance of  
tumorigenic and chemo-resistant CSC like cells (HMLER
shEcad
) (Figure 4). Using these CSC 
like cells as an in vitro model system, Gupta et al. (2009) screened over 16,000 compounds using 
a high-throughput strategy and identified that salinomycin was the only one showing both high 
selectivity and strong efficacy in depleting breast CSCs in vitro (Figure 4).  
 
Figure 4. Research strategies for identification of salinomycin as a CSC inhibitor [88]. 
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Indeed, the pharmacological efficacy of salinomycin is more than 100-fold potency than 
paclitaxel, a commonly used anti-breast cancer drug [89], and displayed profound inhibitory 
activity on tumor seeding, growth and metastasis in NOD/SCID mice in vivo [89]. The 
extraordinary properties and presumed clinical implications of salinomycin discovered by this 
seminal research laid the foundation for a flurry of studies conducted thereafter examining 
salinomycin’s anti-cancer effects in various cancer types and model systems. Table 4 
summarizes the effects of salinomycin on various types of cancer and cancer stem cells, 
providing cumulative compelling evidence for its consideration as a promising anti-cancer drug 
for cancer therapy [66, 67].  
 
1.3.4. Anti-cancer effects of salinomycin 
Following the discovery of salinomycin as a CSC killer, the pharmacological effects of 
salinomycin have been tested in vitro and in vivo (Table 4). For instance, CD133
+
 as a marker of 
cancer stem cell in many cancer types was utilized by Dong et al. to demonstrate that CD133
+
 
colorectal cancer stem cell like cells were sensitive to salinomycin treatment, but not to 
conventional treatment oxaliplatin, in respect to cell proliferation, colony formation, cell 
migration and invasion. The observed effects were accompanied by an up-regulation of the 
epithelial cell marker E-cadherin expression and a suppression of the mesenchymal cell marker 
Vimentin, thereby further implicating the inhibitory effect on the EMT process by salinomycin 
[90]. Consistent with this finding, Basu et al. observed that the mesenchymal-like subpopulations 
within squamous cell carcinomas show resistance to conventional cytotoxic therapy but not to 
salinomycin in vitro and in vivo [91]. Kit
low
CD44
+
CD34
-
 cells in gastrointestinal stromal tumors 
(GIST) are clonogenic cells with the capability of self-renew and differentiation. Bardsley et al. 
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shows that salinomycin blocked the proliferation of Kit
low
CD44
+
CD34
-
 cells and increased their 
sensitivity to imatinib in mice [92]. Human leukemia stem cell-like KG-1a cells are known to 
exhibit resistance to chemotherapeutic drugs via the expression of functional ABC transporters 
such as P-glycoprotein, breast cancer resistance protein (BCRP), and MRP8 which are capable of 
increasing efflux of drugs. Fuchs et al. observed severe cytotoxic effects of salinomycin on KG-
1a cells. Unlike the conventional chemotherapeutic drugs, such as etoposide and doxorubincin, 
salinomycin is able to overcome ABC transporter-mediated multidrug and apoptosis resistance 
[93]. Riccioni and colleagues further reported salinomycin as a P-glycoprotein inhibitor by 
showing its inhibition of the cell growth of P-glycoprotein overexpression multiple drug 
resistance (MDR) cancer cell lines and the P-glycoprotein mediated drug efflux [94]. Moreover, 
the selective cytotoxic effect of salinomycin on tumor stem cells was also detected in 
osteosarcoma in vitro and in vivo. Salinomycin also sensitizes these CSCs to conventional 
chemotherapy drugs including methotrexate, adriamycin, and cisplatin [95]. Very recently, 
salinomycin shows profound cytotoxicity on aldehyde dehydrogenase (ALDH) high stem like 
gastric cancer cell lines surpassing 5-fluorouracil (5-Fu) and cis-diamminedichloroplatinum 
(CDDP) [96]. The combinatorial treatment with trastuzumab and salinomycin by targeting 
HER2-positive cancer cells and CSCs together has led to enhanced cell death in mammospheres 
[97]. Due to its promising anticancer activity, a few clinical case studies of salinomycin have 
been conducted in therapy-resistant cancer patients, e.g. a patient with metastatic invasive ductal 
breast cancer, and revealed potential strong efficacy of salinomycin on eliminating CSCs and 
inducing clinical tumor regression [79]. All the aforementioned studies strongly suggest that 
salinomycin is a new promising agent for cancer therapy. 
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Table 4. Anti-cancer effects of salinomycin 
Cancer Type Cancer Cell 
CSC or Cancer 
Stem Like Cell 
Chemo- or 
Radio- 
resistant 
Cancer Cell 
Reference 
Breast Cancer √ √ √ 
[67, 69, 89, 
97-102] 
T cell Leukemia √  √ [68] 
Human Acute 
Lymphoblastic 
Leukemia 
√  √ [68] 
Human Uterus 
Sarcoma 
√  √ [68, 69] 
Burkitt's Lymphoma √  √ [68] 
Human 
Promyeloblastic 
Leukaemia 
√ √ √ [93] 
Murine 
Gastrointestinal 
Stromal Tumors 
 √  [92] 
Human Liver 
Hepatocellular 
Carcinoma 
√   [69] 
Human Lung 
Adenocarcinoma 
√ √  [103] 
Human Colorectal 
Cancer 
√ √  [90, 98] 
Squamous Cell 
Carcinomas 
√  √ [91, 104] 
Chronic 
Lymphocytic 
Leukemia 
√   [71] 
Osteosarcoma  √ √ [95] 
Prostate Cancer √   [105-107] 
Gastric Cancer  √  [92, 96] 
Pancreatic Cancer √   [108] 
Human Ovarian  
Epithelial Cancer 
√   [94] 
Human Ovarian 
Cancer 
√   [109] 
Human 
Cholangiocarcinoma 
√   [110] 
Human 
Glioblastoma 
√ √  [111, 112] 
Human 
Medulloblastoma 
√   [113] 
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Table 4. Anti-cancer effects of salinomycin (continued) 
Cancer Type Cancer Cell 
CSC or Cancer 
Stem Like Cell 
Chemo- or 
Radio- 
resistant 
Cancer Cell 
Reference 
Human Uterine 
Leiomyoma 
√   [114] 
Human 
Nasopharyngeal 
Carcinoma 
√   [115] 
 
1.3.5. Possible molecular mechanisms of salinomycin 
As mentioned previously, the ionophoric attributes of salinomycin underlying its efficacy 
in protozoa and gram-positive bacteria may not be applicable for explaining its ability to 
eradicate CSCs or circumvent multidrug resistance in responsive cancer cells. Instead, activation 
of unconventional pathways of cell death, enhanced DNA damage, and inhibition of Wnt 
signaling pathway, appear to be more germane to the multi-dimensional anti-CSC and anti-
tumorigenic activities of salinomycin [66-71]. Fuchs and colleagues showed that salinomycin 
induces apoptosis in human cancer cells and overcome apoptosis resistance through a pathway 
independent of activation of p53, caspase, CD95/CD95L system and the proteasome [68]. Kim et 
al. observed that salinomycin induces massive cell apoptosis accompanied with caspase-3 
activation and cleavage of PARP-1 in human prostate cancer cells which is attributed to 
accumulated ROS and mitochondrial membrane depolarization [105]. Ketola and colleagues 
showed that increased levels of oxidative stress play important roles in salinomycin induced 
prostate cancer cell growth inhibition [106].  
Kim et al. demonstrated that combined administration of salinomycin with doxorubicin or 
etoposide led to increased DNA damage and resulted in massive apoptosis in drug resistant 
cancer cells [69]. Mechanistic studies revealed that by increasing DNA damage through 
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enhancing the expression levels of p53 and H2AX and reducing the expression of anti-apoptotic 
p21, salinomycin sensitizes cancer cells to DNA damaging agents, doxorubicin and etoposide 
[69]. In a separate study, salinomycin treatment increased DNA damage and induced G2 arrest, 
thereby, sensitizing cancer cells to radiation treatment. Similarly, salinomycin could suppress the 
elevated p21 level resulted from radiation treatment and promote the expression and activation of 
H2AX and p53 [70]. These studies suggested that patients may benefit from the combined use of 
salinomycin with other chemotherapeutic drugs and radiation therapy. 
A recent report from Verdoodt and colleagues raised, for the first time, that the 
autophagic cell death is another mechanism of induced cell death elicited by salinomycin in 
colon and breast cancer cells [31]. This conclusion was based on the phenomenon that cell death 
induced by salinomycin accompanied with common features of autophagy such as formation of 
the multiple vacuoles and increased uptake of autophagy markers. Most recently, the induction 
of ROS and its consequently activation of JNK pathway have also been observed and linked to 
salinomycin induced autophagic cell death [98]. In addition to the inhibition of cell viability and 
induction of cell death, Kuo et al. observed that salinomycin induces differentiation of head and 
neck squamous cell carcinoma (HNSCC) stem cells associated with the activation of EMT and 
the phosphorylation of Akt [104]. 
Wnt signaling is critical for mammalian development, stem cell renewal, and cancer 
progression [116, 117]. Lu et al. have discovered that nanomolar concentrations of salinomycin 
exhibit profound inhibition on Wnt signaling which is otherwise constitutively activated in 
chronic lymphocytic leukemia cells and the expression of Wnt target genes were subsequently 
down-regulated [71].  This study further showed that salinomycin interrupts Wnt signaling by 
impeding the phosphorylation of lipoprotein receptor related protein 6 (LRP6), a Wnt co- 
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 Figure 5. Anticancer mechanisms of salinomycin [72]. Salinomycin exerts its inhibition on 
Wnt signaling pathway through its suppression on the phosphorylation of LRP6 and the 
expression of β-catenin and p-GSK-3β. It also induces the production of ROS and mitochondrial 
membrane depolarization, which consequently results in the activation of caspase-3, the 
induction of PARP-1cleavage, and the elicitation of DNA damage. These events subsequently 
induce tumor cell death and inhibit cancer cell growth. Moreover salinomycin is able to induce 
autophagic cell death and inhibiting NF-κB pathway and activating p38 MAPK pathway through 
so far unclear mechanisms [69-71, 98, 105-107, 109, 121]. 
 
receptor, and consequently resulting in its degradation [71]. Nuclear factor- B (NF-B) is 
critical for multiple cellular functions, such as cell proliferation and defense of oxidant induced 
cellular damage, which are key elements for tumorigenesis and metastasis [118, 119]. Notably, 
NF-B pathway is activated in prostate stem-like tumor-initiating cells and suppression of NF-
B results in prostate CSC apoptosis [107]. By using a luciferase reporter assay, Ketola et al. 
have shown that growth inhibition and induction of oxidative stress in prostate cancer cells is 
mediated by salinomycin via the suppression of NF-B pathway activity [106]. More recently, 
Zhang and colleagues discovered that salinomycin-induced apoptosis in OV2008 ovarian cancer 
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cells is associated with activating p38 MAPK signaling, a critical pathway in cancer 
development [109, 120]. We have also observed the inhibitory effects of salinomycin on Notch 
and PDGFR signaling pathways [113]. The major pathways affected by salinomycin are 
summarized in Figure 5.  
However, the exact mechanism of how salinomycin regulates the complex cell signaling 
in cancer and CSCs remains largely unclear, especially the cellular targets of salinomycin are not 
known, underscoring the requirement for further studies and elucidation of its mechanism of 
action.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Cell culture  
NB cell lines, SH-SY5Y, IMR32, and SK-N-AS, were obtained from ATCC. Cells were 
maintained in Minimum Essential Medium (MEM) (Cellgro, Catalog # 15-010) supplemented 
with 4 mM L-glutamine (ATCC, Catalog # 30-2214), 100 units/ml penicillin (Gibco, Catalog # 
15140-122), 100 µg/ml streptomycin (Gibco, Catalog # 15140-122), 1% sodium pyruvate 
(Cellgro, Catalog # 25-000-CI ), 1% nonessential amino acids (NEAA, Gibco, Catalog # 11140), 
and 10% fetal bovine serum (FBS, ATCC, Catalog # 30-2020 ) at 37°C with 5% CO2.  
 
2.2. Drugs and chemicals 
Salinomycin (Catalog # S4526) and propidium iodide (PI, Catalog # 81845) were 
purchased from Sigma. Formaldehyde was purchased from Alfa Aesar (Ward Hill, MA). 
Dimethyl sulfoxide (Catalog # 472301), ethanol (absolute, 200 proof, for molecular biology, 
Catalog # E7023), sodium phosphate (Catalog # S3264), sodium bicarbonate (Catalog # S6014), 
sodium chloride (Catalog # S5886), caps (Catalog # C2632), glycine (Catalog # G8898), Trizma 
base (Catalog # T1503), and Triton X-100 (Catalog # T9284)  were obtained from Sigma. 
Glycerol (Catalog # IC800688) was purchased from VWR. Ammonium persulfate (Catalog # 
AC201531000) was purchased from ACROS Organics. 
 
2.3. Transient transfections 
For transient transfection, NB cells were seeded (1 x10
6
 /well) in 6-well plates a day 
before transfection, and TIF1β (Life Technology, Catalog # AM16708), NCL (Qiagen, Catalog #  
GS4691) siRNA, GFP plasmids (Addgene, [Plasmid # 11153]) [122], or GFP-NCL plasmids 
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(Addgene [Plasmid # 28176]) [123] was transfected transiently with Lipofectamine 2000 
(Invitrogen, Catalog # 11668027) in opti-MEM (Life Technology, Catalog # 51985091) reduced 
serum medium for 4 h following the manufacturer’s instruction. Briefly, for each well to be 
transfected, siRNA stock solution (100 µM, in RNase free water) was diluted in 250 µL Opti-
MEM reduced serum medium to final concentrations of 100 or 150 nM and mixed with 15 µL of 
transfection reagent pre-diluted in 250 µL Opti-MEM. For each well to be transfected, plasmids 
DNAs were diluted in 250 µL Opti-MEM reduced serum medium to final amount of 2500 ng. 
After 5 min incubation at room temperature, the transfection mixes were added to the cells in a 
final volume of 2 mL medium. The serum starved cells were then replaced with equal volume of 
MEM medium and kept in culture for 24 h or 48 h at 37°C in a CO2 incubator. Cells were then 
harvested for total RNA for PCR and protein for Western blotting analysis.  
 
2.4. Determination of cell proliferation  
The CellTiter 96® AQueous One Solution Cell Proliferation Assay is a colorimetric 
method to determine the number of viable cells in proliferation or cytotoxicity assays. The 
CellTiter 96
®
 AQueous One Solution Reagent contains a novel tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS] and an electron coupling reagent (phenazine ethosulfate; PES). PES has enhanced 
chemical stability that allows it to be combined with MTS to form a stable solution. The MTS 
tetrazolium compound is bioreduced by cells into a colored formazan product that is soluble in 
tissue culture medium. This conversion is presumably accomplished by NADPH or NADH 
produced by dehydrogenase enzymes in metabolically active cells. The quantity of formazan 
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product as measured by the absorbance at 490nm is directly proportional to the number of living 
cells in culture. 
To analyze the cell proliferation, NB cells (1 x10
5
 /well) maintained in complete medium 
were placed in 96-well plates overnight. Salinomycin at various concentrations or identical 
volume of control (DMSO) was added to the appropriate wells. The cells were treated for 48 hr 
before adding 20 µl of MTS solution (Promega, Catalog # G3580). After 4 hr incubation, the 
number of cells in each well was determined by measuring the optical densities at 490 nm. The 
results were expressed as the percentages of the control cultures.  Experiments were performed 
in triplicate. The results are presented as percentage normalized to the value in the control group. 
 
2.5. PI staining and flow cytometry analysis 
Cells (1 x10
6
 /well) maintained in complete medium were placed in 6-well plates 
overnight. Salinomycin or identical volume of control (DMSO) was added to the appropriate 
wells. The control and treated cells were cultured for additional 24 hr, and the cells were then 
treated with 10 µL ribonuclease A (Catalog # R6513) (10 mg/mL) and 400 µL PI (50 μg/mL) for 
30 min at room temperature in the dark. PI is a fluorescent dye that binds specifically to DNA. 
This property has led to its common use in evaluation of cell cycle, aneuploidy and apoptosis by 
flow cytometry. When excited by a laser light at 488 nm, PI emits a signal that can be monitored 
by the red wavelength detector. Cell cycle data were acquired on the Cell Lab Quanta
TM
 SC 
system (Beckman Coulter) and red fluorescence (PI=DNA content) was collected in FL3 
detector. The percentage of cells in different phases of the cell cycle was computed using Flow 
Jo (TreeStar, OR). At least 10,000 cells were analyzed. 
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2.6. Tumor-sphere formation assay 
Tumorsphere formation assay was performed using a previous reported method [38]. 
Tumorsphere-media consisted of a 50:50 mix of F12 and DMEM (Invitrogen, Catalog # 11320-
033), supplemented with 20 ng/ml EGF (R&D systems, Catalog # 236-EG-01M), 40 ng/ml 
bFGF (R&D systems, Catalog # 233-FB-01M), 1% B27 (Life technology, Catalog # 17504-044) 
and N2 supplements (Life technology, Catalog # 17502-048), 2 µg/ml heparin (Sigma, Catalog # 
H3393), 0.1 mM β-mercaptoethanol (Sigma, Catalog # M6250) and 1× antibiotic/antimycotic 
(Mediatech, Catalog # 30-004-CI).  
 
Table 5. Sphere formation medium 
 Stock Volume 
DMEM:F12 1 x 48.089 mL 
EGF 10 μg/μL 1 μL 
bFGF 5 μg/ml 400 μL 
N2 100 x 500 μL 
Heparin 10 μg/μL 10 μL 
Antibiotics 100 x 500 μL 
B27 (before use) 100 x 500 μL 
 
200 cells were seeded in 200 µl medium into each well in Ultra-low attachment 96 well 
plate (Corning, Catalog #3474). The numbers of tumorsphere formed in each condition were 
counted at day 7 under phase-contrast microscope using the 10x magnification lens. 
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2.7. Binding protein identification 
Binding protein identification was performed by a modified method as previously 
described [124]. Briefly, SH-SY5Y cells (2x10
6
) were treated with salinomycin or DMSO as 
control and 40 min later, cells were lysed with TTL buffer. After centrifugation (32,869 g) using 
Thermo Scientific Microfuge 11R with F14 rotor, 10 min, lysates were diluted to the same final 
volume and protein concentration with cell lysis buffer. All steps were performed on ice or at 
4 °C to prevent premature protein degradation. 50 μg of lysate was then quickly warmed to room 
temperature and proteolysed with 100 ng of thermolysin for 10 min. To stop proteolysis, 0.5 M 
EDTA (pH 8.0) was added to each sample at a 1:10 ratio, mixed well, and placed on ice. 
Samples were then boiled in SDS-PAGE sample buffer and subjected to 12% Tris-HCl SDS-
PAGE and EZBlue
TM
 Gel Staining (Sigma). 
 
2.8. Mass spectrometry analysis 
In-gel trypsin digestion was performed using a similar method to the published 
procedures [125]. Gel bands were excised and destained. Proteins were reduced in-gel with 4 
mM dithiothreitol in 50 mM ammonium bicarbonate for 15 min at 60
o
C. Iodoacetamide was 
added to make 16 mM and alkylation was allowed to proceed for 30 min at room temperature in 
the dark. The reaction was quenched with an additional 3 mM dithiothreitol. The gel slice was 
then equilibrated with ammonium bicarbonate, dehydrated with 100% acetonitrile (ACN), and 
rehydrated in 0.02 µg Trypsin Gold (Promega) in 40 mM ammonium bicarbonate. Digestion was 
allowed to proceed overnight at 37 
o
C. Approximately 50 µl of peptides were extracted. The 
samples were acidified with formic acid to make 0.1% final concentration. Samples were 
analyzed by rpHPLC and spotted onto a MALDI target plate using a TEMPO-LC integrated 
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nanoflow HPLC/spotter. A total of 8.8 μl sample was injected onto a Protecol C18 0.3 x 10 mm 
trap (3 μm 300A pore size). The samples were desalted with 2% ACN/0.1% formic acid v/v 
(Buffer A) for 10 min at a flow rate of 10 μl/min. Peptides were eluted in-line through a 0.1 x 
100 mm Magic AQ C18 (5 μm) column using a 30 min gradient from 100 % Buffer A  to 60% 
Buffer A, /60% Buffer B (98% ACN/0.1% formic acid) at a flow rate of 1 μl/min. Eluate was 
mixed post-column with an equal volume of 10 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA) 
in 75% ACN/0.1% formic acid. The matrix/eluant mix was spotted at 18 sec/spot. Column was 
regenerated at 70% ACN/0.1% formic acid. Spot sets were analyzed on an AB4800 MALDI 
TOF/TOF mass analyzer. The m/z range was 800-4000. Top 10 precursors per spot were selected 
for MS/MS with the weakest precursor first.  
 
2.9. Peptide and protein identification 
Raw spectra were converted to T2D files using 4000 series Explorer version 3.5.28193. 
These files were submitted to Mascot Distiller v.2.3.2. (Matrix Science) to generate uncentroided 
peak lists. Processed spectra were searched against Swissprot database (v. 57.15) using Mascot v. 
2.3.02 (Matrix Science). The search parameters were trypsin with up to one missed cleavage, 
carbamidomethyl (C) as fixed modification. Variable modifications were Acetyl (Protein-N-
term), ammonia loss (N-term C), Gln>pyro-Glu (N-term Q), Oxidation (M). Mass values were 
monoisotopic. Peptide mass tolerance was 100 ppm and fragment ion tolerance was 0.25 Da. 
Mascot searches were combined and analyzed in Scaffold v. 3.00.08 (Proteome Software, Inc.) 
to validate peptide and protein identifications. Peptide identifications with >95% probability and 
protein identifications with > 99% probability and at least two identified peptides were accepted. 
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2.10. Western blotting analysis  
2.10.1. Preparation of cell lysates 
Whole cell lysates were prepared by using Tris-Triton cell lysis buffer (TTL buffer, 1% 
Triton X-100, 50 mM Tris-HCl pH 7.4, 5% glycerol, 100 mM NaCl) supplemented with protease 
inhibitor cocktail (Roche Applied Science) and phosphatase inhibitor cocktail 100x (Cell 
Signaling). 150 µL of cell lysis buffer was added to each well of the 6 well plate and incubated 
for 10 min on ice. Cells in the 6 well plate were then scraped with a plastic scraper.  The lysate 
was collected in 1.5 mL centrifuge tubes and then centrifuged at 24149 g for 10 min at 4 °C. The 
supernatant was collected and stored at -80 °C for further analysis.  
 
Table 6. Cell lysis buffer 
 Volume (3 mL) 
1 M Tris, pH7.4 1.5 mL 
5 M Nacl 60 µL 
Glycerol 150 µL 
Triton X-100 (100%) 30 µL 
Protease inhibitor 600 µL 
dH2O 660 µL 
Proteinase inhibitor stock solution: one tablet in 10 ml water 
 
2.10.2. Protein concentration assay 
The protein concentration in the cell lysates was measured using a Bio-Rad Protein Assay 
Dye Reagent Concentrate (Bio-Rad, Catalog # 500-0006) according to the manufacturer’s 
instructions. The basic principle for the protein concentration assay is based on that the 
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absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 dye shifts from 
465 nm to 595 nm when binding to protein occurs. 
For each 10 μL of protein standard or diluted cell lysate, 200 μL of the diluted Bio-Rad 
Protein Assay Dye Reagent Concentrate were added in each well of a 96-well plate. Solutions 
were incubated at room temperature for 5-20 min and analyzed using a Microplate reader 
(SpectraMax M5, Molecular Devices) at 595 nm. Comparison to a standard curve using bovine 
serum albumin (BSA) standard solutions provides a relative measurement of protein 
concentration. 
 
2.10.3. Preparation of samples for loading into gels 
Sufficiently denature sample protein can ensure target protein fall into the expected 
molecule weight range, because it can reduce the influence from higher structures which may 
lead to variance in electrophoretic velocity. After equilibrated to the same concentration, samples 
were denatured at 95 °C for 5 min in SDS-PAGE sample loading buffer. The samples can be 
stored at -80 °C for further analysis. 
 
Table 7. Protein sample loading buffer (6 x) 
 Volume (10 mL) 
500 mM Tris-HCL, pH 6.8 7 mL 
Glycerol 3 mL 
SDS 1 g 
DTT 0.93 g 
Bromphenol blue 1.2 mg 
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2.10.4. Electrophoresis 
The protein samples were separated using polyacrylamide gel electrophoresis based on 
the premise that the negatively charged (by SDS) protein samples will move to the positively 
charged electrode through the acrylamide mesh of the gel. Smaller proteins migrate faster and 
the proteins are thus separated according to size. The concentration of acrylamide determines the 
resolution of the gel. 
  
Table 8. Polyacrylamide gels for western blotting analysis 
 Resolving Gel (10%) Stacking Gel (4%) 
1.5 M Tris buffer (pH 8.8) 1.9 mL  
1.0 M Tris buffer (pH 6.8)  1 mL 
H2O 2.95 mL 2.25 mL 
Acrylamide/bis-acrylamide 
(30 % solution) 
2.5 mL 625 µL 
10% SDS 75 µL 40 µL 
10 % APS 75 µL 40 µL 
TEMED 3 µL 4 µL 
 
2.10.5. Transfer 
In order to make the proteins accessible to antibody detection, they were transferred by 
electric current from the gel to nitrocellulose membrane. Sponges, filter paper and nitrocellulose 
membrane were soaked in transfer buffer (10 mM CAPS pH 10.5, 20% (v:v) methanol) for 15 
min. The gel was then placed in the “transfer sandwich” composed of sponge-filter paper-gel-
nitrocellulose membrane-filter paper-sponge, and pressed together by a support grid. This 
supported gel sandwich was then placed in the tank filled with transfer buffer. The proteins were 
then electro-transferred to the membrane at constant current (200 mA) for 2 h on ice. 
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2.10.6. Blocking and detection 
Blocking the membrane prevents non-specific background binding of the primary and/or 
secondary antibodies to the membrane. The membrane was soaked in TBST 5% milk solution 
(TBST= 2L 1*TBS +2ml 1*Tween; 10x TBS: 176g NaCl, 24.22g Tris base, 2L water, pH 7.4) 
with shaking at room temperature. 
Western blot relies on the primary antibody to detect the protein of interest from the thousands of 
proteins on the membrane. Using an antibody recognizes the primary antibody (a secondary 
antibody), a protein-primary antibody-secondary antibody sandwich will be established. The 
secondary antibodies are usually labeled with horse radish peroxidase enzyme, which, in the 
presence of its substrates, will emit light during the enzyme catalyzed reaction.  
Immunoblots were probed with antibodies specific for TIF1β (Abcam, Catalog # 
ab10483), NCL (Abcam, Catalog # ab22758), anti-TIF1β-phosphorylated (Ser473) (Biolegend, 
Catalog # 644602), anti-TIF1β-phosphorylated (S824) (Abcam, Catalog # ab10483 ab70369), 
purified anti-Nucleolin-phosphorylated (Thr76/Thr84) (Biolegend, Catalog #  609403), p53 
(Santa Cruz, Catalog # sc-1311-R), Bcl-2 (Santa Cruz, Catalog #  sc-492), cyclin A (Santa Cruz, 
Catalog # sc-751), p21 (Santa Cruz, Catalog #  sc-397), or CD34 (Santa Cruz, Catalog # sc-9095) 
and reprobed with anti--actin antibody (Sigma, Catalog #  A2228) to serve as a loading control. 
Signals of targeted proteins were detected by the Immun-Star HRP peroxide Luminol/ Enhancer 
(Bio–Rad, Catalog # 170-5040) and recorded on BioBlue-XR Autoradiography Film (Alkali 
Scientific). 
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2.11. Analysis of cell surface markers by flow cytometry 
Flow cytometry is a technique for counting particles using electronic detection apparatus, 
which involves labeling cells with a fluorescent marker, and suspending cells in a stream of fluid 
which passes through, and is measured by a fluorescence measuring station. NB cells (1 x10
6
 
/well) maintained in complete medium were placed in 6-well plates overnight. Salinomycin or 
identical volume of control (DMSO) was added to the appropriate wells at 1µM. After 24 hr of 
treatment, the cells were stained with anti-CD133 (Biobyt), or anti-CD34 (Biolegend, Catalog # 
343602), or anti-CD117(c-kit) (Biolegend, Catalog # 313201), and Anti-Mouse IgG FITC 
(Sigma, Catalog #F0257). Mouse IgG (Santa Cruz, Catalog # sc-2025) was used as isotype 
control. Cells were analyzed on BD Accuri
TM 
C6 (BD Biosciences). The percentage of cells with 
different markers was computed using Flow Jo (TreeStar, OR). At least 10,000 cells were 
analyzed. 
 
2.12. Reverse transcription-quantitative PCR (RT-qPCR) 
RNA was isolated from NB cells using the RNeasy Plus Mini Kit (Qiagen, Catalog # 
74136) by following the manufacturer’s protocol. The quantity and purity of RNA were 
determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific). 1 µg of total RNA 
was used to prepare cDNA using SuperScript first-strand synthesis system (Invitrogen) by 
following the instructions provided by the manufacturer. Primers used in this study are listed in 
Table 9 and synthesized by Integrated DNA Technology. The original cDNA reaction mixture 
was diluted to one-tenth of the reaction volume. 2 µl of the diluted cDNA was used as the 
template in the quantitative PCR reaction. PCR amplification was performed using SYBR 
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GreenER qPCR SuperMix (Invitrogen) and 7500 Fast & 7500 Real-Time PCR System (Life 
technology). 
 
Table 9. Primers and conditions used for the qRT-PCR 
Gene Primer Sequences (5'-3') 
Sizes of 
PCR 
Products 
(bp) 
Annealing 
Temperature 
(°C) 
Cycle of 
Amplification 
CD133 
Forward: AGAAATGCACCAGCGACAGA 
Reverse: CGCCTTGTCCTTGGTAGTGT 
256 60 45 
CD34 
Forward: CCCAGCCAACGTTTCAACTC 
Reverse: CGCACAGCTGGAGGTCTTAT 
232 60 45 
c-Kit 
Forward: TGACTTACGACAGGCTCGTG 
Reverse: CAGAAGTCTTGCCCACATCG 
258 60 45 
GAPD
H 
Forward: GAGTCAACGGATTTGGTCGT 
Reverse:TTGATTTTGGAGGGATCTCG 
234 57 45 
 
2.13. Immunoprecipitation assay 
Immunoprecipitation (IP) was conducted using the Pierce crosslink magnetic IP/Co-IP kit 
(Thermo Scientific, Catalog # 88805) according to the manufacturer’s instructions. Briefly, 
whole cell lysates were prepared by using Tris-Triton cell lysis buffer (1% Triton X-100, 50 mM 
Tris-HCl pH 7.4, 5% glycerol, 100 mM NaCl) supplemented with protease inhibitor cocktail 
(Roche Applied Science). Cell lysates were then incubated with 10 μM salinomycin for 1 hr at 
4°C. 5μg of antibody was used for each IP reaction and cross-linked to Protein A/G magnetic 
beads using disuccinimidyl suberate (DSS). For each IP reaction, 2 mg of protein lysates were 
reacted with specific antibody cross-linked beads overnight at 4 °C. The beads were then 
collected with a magnet stand and washed three times with washing buffer (0.2% Tween PBS). 
Bound proteins were eluted by heating at 95°C in 6 x SDS-PAGE sample buffer and subjected to 
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Western blotting analysis. Immunoblots were probed with antibodies specific for TIF1β (Abcam, 
Catalog # ab10483) and NCL (Abcam, Catalog # ab22758). Anti-salinomycin antibody was 
purchased from Abcam (Catalog # ab123955). Normal sheep IgG (Santa Cruz, Catalog # sc-
2717) and rabbit IgG (Santa Cruz, Catalog # 2027) were served as control. 
 
2.14. Immunofluorescence 
SH-SY5Y cells were fixed using 4% formaldehyde for 15 min at room temperature and 
treated with 0.1% Triton X-100 for 15 min and blocked by 5% BSA for 20 min, then incubated 
overnight at 4°C with the anti-NCL (Abcam, Catalog # ab22758) and anti-CD34 (R&D Systems, 
Catalog # MAB72271 ) primary antibodies. Cells were then incubated with goat anti-mouse IgG-
R-Phycoerythrin (Sigma, Catalog # P9287) and goat anti-rabbit IgG-FITC (Santa cruz, Catalog # 
sc-2012) secondary antibodies for 2 hr at room temperature. Nuclei were stained with 0.5 μg/ml 
Hoechst 33258 dye (Invitrogen, Catalog # H3569) for 5 min. The cells were visualized and 
photographed using Leica DMi 8 fluorescence microscope. 
 
2.15. Chromatin Immuno-Precipitation (ChIP)-qPCR assay 
Cells (5 x10
6
 /well) maintained in complete medium were placed in 10 cm cell culture 
plate overnight. The next day cells were treated with salinomycin for 4 hr and later cross-linked 
with 10 ml of 1% formaldehyde for 30 min at room temperature. The reaction was ceased by 
adding 1 ml of 1.37 M glycine and mixed immediately. The plates were then placed on ice and 
washed thrice with Buffer A (PBS supplemented with protease inhibitor cocktail). Cells were 
then trypsinized and the detached cells were harvested by centrifugation at 168 g for 5 min at 
4°C. The pellet was re-suspended in 500 µl of Buffer B (0.625 mM Hepes, pH7.8, 1.5mM 
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MgCl2, 0.03M KCl, 0.01% Igepal CA-630, 1mM DTT) and kept on ice for 10 min. The cells 
were dounced 10-15 times to release the nuclei. The released nuclei were then harvested by 
centrifuging at 336 g for 5 min. The cells were re-suspended in 500 µl of Buffer C (50mM Hepes, 
pH7.9, 4mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) 
supplemented with protease inhibitor cocktail. Sonication was performed (using Branson Digital 
sonifier ®) at 30% amplitude for 10 sec each three times. The samples were then centrifuged at 
32869 g for 15 min at 4°C. The supernatant was collected and pre-cleaned with 50 µl of the 
Protein-A sepharose
TM
 CL–4B (GE Healthcare) slurry (80 mg in Buffer C per 500 µl of the 
lysate) with constant rotation for 1 h in a cold room. The samples were centrifuged at 336 g for 5 
min and the supernatant containing the pre-cleaned chromatin was collected. 50 µl aliquot of 
each sample was saved to serve as the Input DNA.  5 µl of primary antibody (Anti-NCL (abcam) 
or control Rabbit IgG (Santa Cruz) were added to the rest of the sample  and incubated in a cold 
room with constant rotation for overnight. Next day, 50 µl of Protein-A sepharose slurry was 
added to each sample and incubated for 2 h with constant rotation in the cold room. Then, 
centrifugation was performed at 1677 g for 3 min. The beads were then washed twice each time 
with Buffer C, Buffer D (2.5 mM Hepes, pH7.9, 0.5 M NaCl, 1mM EDTA, 1% Triton X-100, 
0.1% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail), Buffer E (2.5 mM Hepes, 
pH7.9, 12.5 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS) 
and TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). 200 µl of Elution buffer (0.05 M Tris, pH 8.0, 
1mM EDTA, 0.05% SDS, 0.05M sodium bicarbonate) was then added to the beads and 
incubated at 65°C for 10 min. Centrifugation was performed at 32869 g for 1 min and the 
supernatant was collected. Beads were eluted again to obtain a total 400 µl of elute. In parallel, 
the saved input DNA was thawed and 350 µl of elution buffer was added to bring the total 
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volume up to 400 µl. 16.5 µl of 5M NaCl was added to each tube and incubated at 65°C 
overnight for reverse-cross-linking. 2 µl of RNAse (Sigma) was added the next day and 
incubated at 37°C for 1 h. 4 µl of EDTA (0.5 M) and 2 µl of Proteinase K (Qiagen) was added 
and incubated at 42°C for 2 h. DNA were then extracted with chloroform/isoamyalcoholonce by 
centrifuging at 32869 g for 10 min. The aqueous phase was collected to which 40 µl of sodium-
acetate (3M) and 1 ml of ethanol was added and was incubated at -20°C overnight for 
precipitation. The samples were centrifuged at 32869 g for 30 min the next day and the pellets 
were washed once with 80% EtOH. The immuno-precipitate (IP) and the Input sample pellets 
were re-suspended in 50 µl of Tris, pH 8.5. The chromatin precipitates were then taken for qPCR. 
The buffers used for the ChIP assay are listed in Table 10.  
 
Table 10. Buffer components for ChIP-qPCR 
Buffer A Volume in 50 ml stock (ml) 
1X PBS 
Protein cocktail inhibitor 
50 
1 tablet 
Buffer B Volume in 50 ml stock (ml) 
25 mM Hepes, pH7.8 
50 mM MgCl2 
1 M KCl 
0.1% Igepal CA-630 
50 mM DTT 
Distilled water 
Protein cocktail inhibitor 
1.25 
1.5 
0.5 
0.05 
1 
45.7 
1 tablet 
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Table 10. Buffer components for ChIP-qPCR (continued) 
Buffer C Volume in 50 ml stock (ml) 
1 M Hepes, pH7.9 
140 mM NaCl 
50 mM EDTA 
20% Triton X-100 
10% sodium deoxycholate 
20% SDS 
Distilled water 
Protein cocktail inhibitor 
2.5 
1.4 
1 
2.5 
0.5 
0.25 
41.85 
1 tablet 
Buffer D Volume in 50 ml stock (ml) 
50 mM Hepes, pH7.9 
5 M NaCl    
50 mM EDTA    
20% Triton X-100   
10% sodium deoxycholate 
 20% SDS   
Distilled water  
 Protein cocktail inhibitor  
2.5 
5 
1 
2.5 
0.5 
0.25 
38.25 
1 tablet 
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Table 10. Buffer components for ChIP-qPCR (continued) 
Buffer E Volume in 50 ml stock (ml) 
50 mM Hepes, pH7.9  
250 mM NaCl  
50 mM EDTA  
2.5 
2.5 
1 
10% sodium deoxycholate 
20% SDS 
20% Triton X-100 
Distilled water 
Protein cocktail inhibitor 
0.5 
0.25 
2.5 
40.75 
1 tablet 
 Elution buffer Volume in 50 ml stock (ml) 
1 M Tris, pH 8.0 
50 mM EDTA  
1% SDS 
1 M sodium bicarbonate 
Distilled water 
2.5 
1 
2.5 
2.5 
41.5 
The following primers were used for quantitative analysis (Table 11). 
Table 11. Primers and conditions used for the ChIP-qPCR 
Gene Primer Sequences (5'-3') 
Sizes of 
PCR 
Products 
(bp) 
Annealing 
Temperature 
(°C) 
Cycles  
CD34 
promoter 
Forward: GATGGTGATGGGGAACTAAATGG 
Reverse: GCCAGTAACAATCTTGCAAAAGG 
338 60 45 
GAPDH 
Forward: GAGTCAACGGATTTGGTCGT 
Reverse: TTGATTTTGGAGGGATCTCG 
234 57 45 
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2.16. The expression levels of TIF1β and NCL in NB tumors and the correlation with NB 
patients’ outcomes 
A set of 498 NB samples previously detected by microarray in the database was used for 
TIF1β and NCL expression [126]. Using the R2 software (http://r2.amc.nl), we analyzed the 
expression levels of TIF1β and NCL in NBs and determined the correlation of TIF1β and NCL 
levels in NBs with their clinical outcomes. The expression levels of TIF1β and NCL were also 
analyzed in different subgroups based on MYCN amplification, risk group and INSS stage. The 
statistical analysis of each gene in different groups of NBs was evaluated by one-way ANOVA. 
The correlations between the expression levels of TIF1β and NCL with patients’ survival were 
analyzed using chi-squared test and Kaplan-Meier curves. Survival was measured from the time 
of initial diagnosis until the date of death or the date of last follow up owing to progressive 
nature of the disease. The survival distribution was estimated using Kaplan-Meier curves, and 
optimal cut-off selection (chi-squared test p-value). P-values < 0.05 were considered to be 
statistically significant. 
 
2.17. Statistical analysis 
All quantitative data from in vitro assays are represented as mean  standard deviation 
(SD). Statistical tests were performed with the Minitab 16.1.1 software package. Comparisons 
between two groups were carried out using paired student’s t test. p < 0.05 was used as the 
criterion for statistical significance. 
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CHAPTER 3. TO DETERMINE THE ANTI-CANCER EFFECTS OF 
SALINOMYCIN IN NB 
3.1. Introduction 
Neuroblastoma (NB) is the most frequently diagnosed solid extracranial malignancy in 
the pediatric population. More than 30-50% of high-risk cases remain incurable due to the 
emergence of therapy-resistance [1, 127]. The failure to respond to chemotherapeutic regimens 
and fear of disease relapse and distant organ dissemination are underpinned by the presence of 
CSCs, which are not effectively eliminated by conventional chemotherapies [37, 38, 56]. The 
unsatisfactory clinical outcomes of NB underscore the need for the development of novel 
treatment.  
Recently, a stem cell like population in NB, namely NB-CSCs, has been observed with 
higher potential for treatment resistance [37-39]. Studies also indicate that most of NB cell lines 
contain a subpopulation expressing stem cell surface markers, e.g., CD133, c-kit, and nestin  [37, 
38]. Based on the expression levels of stem cell markers, differentiation potential and the 
capacity for tumorigenisis, NB cells may be classified as neuroblastic (N), substrate-adherent 
(S), and intermediate (I) phenotypes [37, 128]. Of note, N- and I-NB cell types are less 
differentiated with higher potential to form tumors in vivo compared to S-type that is considered 
to be non-tumorigenic [37, 128].  
In this study, we used three NB cell lines, SH-SY5Y, IMR32, and SK-N-AS, 
respectively, as a preclinical model to determine the unexplored efficacy of salinomycin on NB 
and the targets of salinomycin. SH-SY5Y and IMR32 containing N-type cells are considered as 
CSC rich cell lines, while SK-N-AS is a typical S-type cell line [37, 128].  
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3.2. Results and Discussions 
3.2.1. Determining the effects of Salinomycin on NB cell proliferation 
To determine the efficacy of salinomycin on NB cells, we first analyzed the effects of 
salinomycin on NB cell proliferation in three NB cell lines. Cells were treated with various 
concentrations (0.25 – 4 μM) of salinomycin and analyzed for cell proliferation by using MTS 
assay. Our data showed that salinomycin exhibited marked inhibition of cell proliferation in a 
dosage dependent manner, and the IC50 values for the inhibitory effects of salinomycin on cell 
proliferation at 48 h were at 1μM for the N-type tumorigenic SH-SY5Y and IMR32 cells, and > 
4 μM for the S-type non-tumorigenic SK-N-AS cells [37, 128], indicating salinomycin is more 
effective in tumorigenic cells (Figure 6)  . 
 
Figure 6. The effects of salinomycin on NB cell proliferation. Salinomycin suppresses NB cell 
proliferation. Cell viability was assessed using MTS assay 48 hr after salinomycin treatment. 
*p<0.05, **p<0.01, and ***p<0.001. 
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In addition, the IC50 value of salinomycin in N-type NB cells is much lower than some currently 
being used chemotherapeutic drugs for NB, e.g. carboplatin, in the same in vitro cell line systems 
with reduced possibility of side effects (Table 12) [19].  
 
Table 12. Comparison of the anti-proliferative effects of salinomycin with other 
chemotherapeutic drugs in NB cells 
Chemotherapeutic 
Drug 
IC 50 (μM) (72hr) 
Major Side effects 
SH-SY5Y IMR32 
Etoposide 0.3 3 Bone marrow suppression 
Cyclophosphamide 1 3 
Damage to bladder (carcinogenic); 
Bone marrow suppression 
Carboplatin 12 70 
Damage to Kidney; Bone marrow 
suppression 
Doxorubincin 0.1 8 Damage to heart 
Vincristin 0.01 0.1 Damage to nerves and kidney 
Melphalan 3 30 Bone marrow suppression 
  
IC 50 (μM) (48hr) 
  
Salinomycin 1 1 
Few side effects on normal cells; 
requires further investigation 
 
3.2.2. Determining the role of salinomycin on NB cell cycle progression 
We then determined the effects of salinomycin on cell cycle progression using PI staining 
analysis. We observed that salinomycin induces cell death as indicated by an increased sub-G0 
population. In addition, in all the three cell lines, a significant number of cells (P<0.05) were 
found to be arrested at G2 phases of the cell cycle in salinomycin treated cells (Figure 7).  
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The percentage of cells in the G2 phase were elevated from 16.5%, 19.9%, and 9.5% to 
30.3%, 44.3%, and 27.5% for SH-SY5Y, IMR32, and SK-N-AS cells respectively in 
salinomycin treated cells as shown in Figure 7. The G2/M checkpoint is an important cell cycle 
checkpoint that insures that cells do not enter mitosis before they have a chance to repair 
damaged DNA [129]. The cell cycle arrest on G2 phases may contribute to the inhibitory effects 
of salinomycin on NB cells. 
 
Figure 7. The effect of salinomycin on NB cell cycle progression. Quantification of cell 
population in each cell phase by PI staining. Cells treated with salinomycin or control vehicle for 
24 hr, and the cells were stained with PI and analyzed by flow cytometry. *p<0.05, **p<0.01, 
and ***p<0.001. 
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3.2.3. Determining the role of salinomycin on cyclin A and p21 expression 
Cyclin A is known to regulate the G2/M transition in a p53 dependent manner [130, 131]. 
We then analyzed the expression of cyclin A and the anti-apoptotic protein p21[132] in response 
to salinomycin treatment.  
In our study, we treated NB cells with 1 μM, 4 μM  salinomycin or vehicle control for 24 
hr and analyzed the protein expression of cyclin A and p21. Our data show that the levels of 
cyclin A were significantly up-regulated while the anti-apoptotic protein p21 was down-
regulated  in NB cells in a dose dependent manner (Figure 8). These results are consistent with 
salinomycin’s inhibitory effect on cell cycle progression and promoting effect on cell death. 
 
Figure 8. Effects of salinomycin on cyclin A and p21 expression. (A) Cells were treated with 
salinomycin at indicated concentrations for 24 hr and whole cell lysates were extracted for 
western blotting. Immunoblots were probed with antibodies specific for cyclin A or p21, and 
reprobed with anti-β-actin antibody to serve as a loading control. (B) Quantification of 
salinomycin’s effects on cyclin A expression. (C) Quantification of salinomycin’s effects on p21 
expression. *p<0.05 and **p<0.01. 
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3.2.4. Determining the role of salinomycin on NB tumorsphere formation  
As introduced earlier, CSCs have been defined functionally by two major criteria: their 
ability to undergo self-renewal and their ability to produce differentiated progeny. A sphere 
formation assay is used to identify the stem cell characteristic of self-renewal in vitro since only 
self-renewal cells are able to form the 3D sphere-shaped structure (tumorsphere, in the case of 
cancer cells) in suspension [133].  
To determine the efficacy of salinomycin on NB cells and CSCs, we then analyzed the 
effects of salinomycin on NB cell tumorsphere formation in three NB cell lines. In response to 
salinomycin treatments, we observed significant suppressive effects on tumorsphere formation in 
SH-SY5Y and IMR32 cells. As expected, the s-type non-tumorigenic SK-N-AS cells did not 
form tumorsphere in culture. These results indicate that salinomycin suppresses the activities of 
NB CSCs (Figure 9). 
 
Figure 9. Salinomycin inhibits tumorsphere formation of NB cells. (A) All tested NB cell 
lines except non-tumorigenic SK-N-AS form tumorsphere and salinomycin suppresses NB cell 
tumorsphere formation. Cells treated with salinomycin or DMSO control were grown in 
tumorsphere-media, and the number of tumorspheres was counted at day 7, ***p<0.001. (B) 
Salinomycin suppresses NB cell tumorsphere formation. Cells treated with salinomycin or 
DMSO control were grown in tumorsphere-media. Images were captured at day 7.  
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3.2.5. Determining the role of salinomycin on NB CSC like population 
CD133 and c-kit are CSC related surface markers and the existence of NB cells 
expressing these molecules is implicated in NB treatment failure [37, 38]. The effect of 
salinomycin on the suppression of NB cell tumorsphere formation suggests that salinomycin 
suppresses the NB-CSCs since a tumorsphere is a spherical formation developed from the 
proliferation of CSCs. To verify the possible roles of its inhibitory effects on NB CSCs, NB cells 
were treated with salinomycin or vehicle control for 24 hr and the amount of CSC-like (CD133
+
 
and c-kit
+
) NB cells were detected by Flow Cytometry.  
As expected, the S-type SK-N-AS cells showed significantly lower levels or no 
expression of the three markers compared with the other two N-type tumorigenic NB cells 
(Figure 10). Salinomycin showed significant inhibitory effects on CD133
+ 
and c-kit
+ 
NB cells as 
shown in Figure 10. A previous report suggested that c-kit and its ligand stem cell factor (SCF) 
are preferentially expressed in NB tumors with MYCN amplification [134]. Consistent with this 
finding, our data showed that the IMR32 cell line with MYCN amplification contains 
significantly higher (P<0.001) amount of c-kit
+
 cells in comparison with the other two MYCN 
non-amplified cell lines; treatment with salinomycin resulted in approximately 50% reduction of 
the c-kit
+
 cells in SH-SY5Y and SK-N-AS cells, and more than 70% decrease of the c-kit
+
 
population in IMR32 cells (Figure 10).  
  
  
 
4
7
 
 
Figure. 10. Salinomycin selectively inhibits CSC-like population (CD133
+
 and c-kit
+
 NB cells). (A) After treated with salinomycin 
or vehicle control for 24 hr, NB cells were stained with anti-CD133, anti-c-kit or IgG control and anti-Mouse IgG- FITC and analyzed 
using a flow cytometry. Representative results for each marker are shown. (B) Salinomycin inhibits CD133
+
 NB cells. (C) 
Salinomycin inhibits c-kit+ NB cells. Data represent the mean ± SD of triplicate experiments. *p<0.05, **p<0.01. 
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3.2.6. Determining the role of salinomycin on p53 
It has been reported that p53 is required for the maintenance of the neuroblastic 
tumorigenic phenotype of NB and the down-regulation of p53 results in the conversion of N-type 
tumorigenic NB cells to the substrate-adherent fibroblast-like non-tumorigenic S-type NB cells 
[135].  
To test the effect of salinomycin on p53, we analyzed the expression levels of p53 in NB 
cells upon salinomycin treatment. Our data show that salinomycin treatment markedly reduced 
the expression level of p53 in all the three cell lines (Figure 11). 
 
Figure 11. Salinomycin down-regulates p53 expression. (A) Cells were treated with 
salinomycin at indicated concentrations for 24 hr and whole cell lysates were extracted for 
western blotting. Immunoblots were probed with antibodies specific for p53, and reprobed with 
anti-β-actin antibody to serve as a loading control. (B) Quantification of salinomycin’s effects on 
p53 expression. *p<0.05 and **p<0.01.  
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CHAPTER 4. TO IDENTIFY THE FUNCTIONAL BINDING TARGET OF 
SALINOMYCIN IN NB 
4.1. Introduction 
To explore approaches that selectively eradicate the CSC population is a novel and 
potentially promising direction of improving anti-cancer therapy. The anti-cancer and anti-CSC 
effects of salinomycin have been observed in many types of cancers in vitro and in vivo [66]. We 
have observed profound cytotoxicity of salinomycin against NB cells in vitro in our preliminary 
study. The expanding evidence for salinomycin’s remarkable efficacy and anti-CSC capability 
provides strong impetus for the need for continued study to elucidate its action mechanisms. To 
this end, identification of its binding proteins is pivotal. 
Many therapeutic drugs and preventive agents initiate their biological effects by binding 
directly to the proteins in human cells. To discover and identify the target molecules for various 
clinical therapeutic modalities has many benefits: (1) to provide researchers and medical experts 
understanding of the mechanisms and to reduce the side effects, (2) to lay a foundation for 
personalized medicine by identifying patients with a deficiency in drug targets, for treatment 
using alternative therapies, (3) facilitate new drug discoveries by using the targets to search for 
more effective drugs or new agents, (4) identify drugs and chemopreventive agents that have 
more than one target and can be used for different therapeutic and preventive purposes. Thus, in 
this study, we used comprehensive approaches to identify functional binding targets of 
salinomycin in NB. 
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4.2. Results and Discussions 
4.2.1. Identification of potential binding targets of salinomycin by using DARTS analysis  
To understand the underlying mechanism of salinomycin on NB and NB CSC-like 
population, we postulate the existence of cellular protein targets that bind and interact with 
salinomycin. To test and evaluate this hypothesis, we first applied a modified “drug affinity 
responsive target stability” (DARTS) method to identify salinomycin’s binding proteins in SH-
SY5Y cells [124]. This approach is based on the premise that, when proteins interact with 
molecules such as a drug, to form a drug-protein complex, such interactions may result in 
conformational changes, which consequently reduces the sensitivity to proteolytic enzymes 
(Figure 12).  
 
Figure 12. Schematic presentation of the procedures of chemoproteomic strategy. 
 
In this study, we performed the above mentioned DARTS method using biochemical 
affinity beads coupled with chemoproteomics to identify salinomycin binding proteins and to 
explore the interaction of salinomycin with its binding proteins in NB cells that harbor cancer 
stem cell characters [37, 38, 56].
 
As shown in Figure 13, the bands on the gel with increased 
densities upon the salinomycin treatment compared to the control were considered drug binding 
target protein containing lysates and were selected for mass spectrometry analysis. 
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Figure 13. Identification of salinomycin potential targets. Intact SH-SY5Y cells were treated 
with salinomycin and whole cell lysates were subjected to thermolysin digestion and EZBlue
TM
 
Gel Staining. A comparison of the gel separation patterns of the mock cell lysate with 
salinomycin-treated cell lysate after thermolysin digestion reveals existence of several unique 
salinomysin-protected bands. 
 
4.2.2. Analysis of potential binding targets  
The mass spectrometry analysis provided us a list of binding target protein candidates for 
salinomycin (Figure 14). We then analyzed the candidate proteins at size, probability of hits, and 
biological functions of putative targets. By excluding proteins exist in all types of cells and 
functionally irrelevant with CSCs, e.g. Spectrin alpha II (SPTA2), and proteins with relatively 
low hits, e.g., Calreticulin, and proteins less likely to be involved in CSC and NB development, 
e.g., transitional endoplasmic reticulum ATPase. Transcription intermediary factor 1-beta (TIF1β) 
and Nucleolin (NCL), which are actively associated with stem cell functions and cancer 
progression [136, 137], were selected for further investigation. 
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Figure 14. Mass spectrometry analysis of potential salinomycin binding targets. (A) The 
number of hits of unique spectra for each protein hit. (B) The summary of protein hits. Different 
colors represent different probability for the peptide matching as displayed in the table. To 
identify the peptides and proteins, raw spectra were converted to T2D files using 4000 series 
Explorer version 3.5.28193. These files were submitted to Mascot Distiller v.2.3.2. (Matrix 
Science) to generate uncentroided peak lists. Processed spectra were searched against Swissprot 
database (v. 57.15) using Mascot v. 2.3.02 (Matrix Science). Mascot searches were combined 
and analyzed in Scaffold v. 3.00.08 (Proteome Software, Inc.) to validate peptide and protein 
identifications. Peptide identifications with >95% probability and protein identifications with > 
99% probability and at least two identified peptides were accepted. 
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4.2.3. Confirmation of the binding targets by western blotting analysis 
To evaluate these two potential targets, we applied the NB cell lysate to the DARTS 
method in both SH-SY5Y and IMR32 cell lines followed by western blotting analysis with 
antibodies specific to NCL and TIF1β (Figure 15). As shown by Figure 15, protein bands with 
increased densities upon the salinomycin treatment compared to the control for NCL and TIF1β 
were both observed, revealed that NCL and TIF1β are potential binding proteins of salinomycin. 
 
Figure 15. Confirmation of NCL and TIF1β as salinomycin binding targets by Western 
blotting. Intact SH-SY5Y cells were treated with salinomycin at indicated concentration for 24 
hr and whole cell lysates were subjected to DARTS and western blotting analysis with antibodies 
against NCL and TIF1β. β-actin served as a loading control. 
 
4.2.4. Confirmation of the direct binding by IP assay 
To further confirm that salinomycin interacts with NCL and TIF1β, an IP assay using 
affinity beads was performed. As shown in Figure 16, when applied anti-salinomycin conjugated 
beads to the total protein lysate for the immunoprecipitation assay, both NCL and TIF1β are 
detected. We thus concluded that NCL and TIF1β are binding protein targets of salinomycin.  
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In addition, by using anti-NCL conjugated beads for IP, we show that NCL binds to 
TIF1β (Figure 16B). This is in line with previous report showing the co-IP of NCL and TIF1β 
and their possible role in enhancing tumor cell growth.[138] 
Figure 16. Identification of salinomycin binding to NCL and TIF1β using anti-salinomycin 
affinity beads. (A) Binding of salinomycin to NCL by IP assay using anti-salinomycin 
conjugated affinity beads. (B) Binding of salinomycin to TIF1β by IP assay using anti-
salinomycin conjugated affinity beads and the binding of NCL to TIF1β by IP assay using anti-
NCL conjugated affinity beads followed by immunobloting analysis using anti-TIF1β antibody. 
The specific target proteins are indicated by arrows. 
 
4.2.5. Baseline expression of TIF1β and NCL in NB cell lines 
TIF1β and NCL are multifunctional proteins involved in numerous cellular processes, 
including cell growth, differentiation, proliferation, apoptosis, cell cycle progression, and are 
critical for stem cell maintenance and differentiation [136, 137]. To explore the possible roles of 
TIF1β and NCL in NB cells, we first analyzed the baseline expression of TIF1β and NCL in NB 
cell lines (Figure 17).  
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Both TIF1β and NCL are expressed in a relatively high level in NB cell lines. The 
expression level was highest in the MYCN amplified cell line IMR32 and was lowest in the S-
type non-tumorigenic cell line SK-N-AS for both TIF1β and NCL in the tested three NB cell 
lines. 
 
Figure 17. Expression baseline levels of TIF1β and NCL in NB cells. (A) Whole cell lysates 
were analyzed by Western blotting. β-actin served as a loading control. (B) Quantification of 
basal levels of TIF1β and NCL in three NB cell lines from Western blotting analysis. 
 
4.2.6. Knockdown of TIF1β and/or NCL in NB cell lines 
To explore the possible roles of TIF1β and NCL in NB cells, we performed the siRNA 
knockdown experiment using siRNAs against TIF1β or NCL, as well as the combination. The 
knockdown efficiency are shown in Figure 18.  
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Figure 18. Efficiency of siRNA knockdown of TIF1β and NCL in SH-SY5Y cells. Cells were 
treated with siRNAs specific to TIF1β and NCL respectively for 48 hr, and the knockdown 
efficiency was confirmed by Western blotting analysis. 
 
4.2.7. Determining the effects of knockdown of TIF1β and/or NCL on NB cell proliferation 
and salinomycin’s anti-proliferative effects 
TIF1β and NCL were both shown to be implicated with cancer cell proliferation [139, 
140]. To explore the possible roles of TIF1β and NCL in NB cells, we analyzed the effects of 
siRNAs against TIF1β and/or NCL and the combination of TIF1β and NCL siRNAs with 
salinomycin on NB cell proliferation. As shown in Figure 19, knockdown of TIF1β or NCL 
reduced the cell proliferation by 10% and 30%. Double knockdown of TIF1β and NCL reduced 
the cell proliferation by about 55%, indicating the important roles of these two molecules in NB 
cell proliferation. Moreover, notably, the combination of salinomycin with knockdown TIF1β 
and NCL had no additional effects on cell proliferation, suggesting that TIF1β and NCL are 
functional targets of salinomycin.  
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Figure 19. Salinomycin suppresses NB cell proliferation through NCL and TIF1β. Cells 
incubated with NCL and TIF1β siRNAs overnight were treated with DMSO control or 1 μM 
salinomycin. After 24 hr, the number of viable cells in each well was determined using MTS 
assay. */#p<0.05, **/##p<0.01, and ***/###p<0.001. 
 
4.2.8. Determining the effects of knockdown of TIF1β and/or NCL on NB cell tumorsphere 
formation and salinomycin’s anti-tumorigenic effects 
To explore the possible roles of TIF1β and NCL in NB CSCs, we analyzed the effects of 
siRNAs against TIF1β and/or NCL and the combination of TIF1β and NCL siRNAs with 
salinomycin on NB cell tumorsphere formation. As shown in Figure 20, knockdown of TIF1β or 
NCL markedly suppressed tumorsphere formation by 40% and 55% respectively. Notably, the 
combination of knockdown of TIF1β and NCL with salinomycin had no additional effects on 
tumorsphere formation, suggesting that TIF1β and NCL are functional targets of salinomycin.  
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Figure 20. Tumorsphere formation assay of NB cells with NCL and TIF1β and salinomycin 
treatment. SH-SY5Y cells incubated with NCL and TIF1β siRNAs overnight were treated with 
DMSO control or 0.25 μM salinomycin. After 7 days, the number of tumorspheres in each well 
was determined under phase-contrast microscope. */#p<0.05, **/##p<0.01, and ***/###p<0.001. 
 
  
  
59 
 
CHAPTER 5. TO DETERMINE THE MECHNISM OF THE 
INTERACTION OF SALINOMYCIN WITH ITS BINDING TARGETS  
5.1. Introduction 
TIF1β and NCL are multifunctional proteins implicated in diverse cellular processes, 
including cell growth, differentiation, apoptosis, and cell cycle progression. TIF1β is also known 
as KAP1 (KRAB domain-associated protein) or Trim28 (Tripartite motif-containing 28). 
Elevated levels of TIF1β protein have been detected in many types of cancers and associated 
with a significantly lower survival rate in cancer patients [141-143]. Also, mice lacking TIF1β 
are defective in early postimplantation development [137]. More importantly, TIF1β was 
specifically identified as a self-renewal gene through a genome-wide RNAi screen in mouse 
embryonic stem (ES) cells, and, interestingly, its depletion resulted in cell differentiation into the 
primitive ectodermal lineage.[144]   
NCL, also known as C23, is an RNA- and protein-binding protein, highly conserved and 
ubiquitously expressed among eukaryotes [145]. Several observations suggest that NCL 
functions as an mRNA-stabilizing factor for the anti-apoptotic Bcl-2 protein to act as a 
fundamental promoter for cell survival and proliferation [146-148]. High levels of NCL in 
tumors and actively dividing cells have also been widely observed [140]. The absence of NCL 
results in cell growth arrest at G2 phase, cell apoptosis as well as nucleolar disruption [149]; 
suggesting it is required for cell proliferation and survival. NCL is, hence, used as a marker for 
cell growth and proliferation[140]. In addition to its fundamental role in cell proliferation, NCL 
expression was found to be deregulated during NB cell differentiation [150]. Moreover, NCL has 
been further demonstrated to be required for the maintenance of embryonic stem cell self-
renewal.[136]  
  
60 
 
The unique properties of TIF1β and NCL, therefore, make these two molecules very 
attractive targets for cancer therapeutics. The identification of TIF1β and NCL as salinomycin’s 
binding targets further indicates that TIF1 and NCL are important for salinomycin’s anti-cancer 
effects in NB cells.  
 
5.2. Results and Discussions 
5.2.1. Effect of salinomycin on TIF1β expression in NB cells 
To determine the modulation of TIF1 by salinomycin, we first analyzed the effect of 
salinomycin on the protein expression of TIF1 in NB cells. Our data show that NB cells under 
salinomycin treatment for 24 hr, 48 hr, as well as 72 hr did not show significantly altered 
expression levels of TIF1 (Figure 21). 
 
Figure 21. Effects of salinomycin on TIF1β expression levels in NB cells. (A) Expression 
levels of TIF1β in NB cells at 24 hr post salinomycin treatment. (B) Expression levels of TIF1β 
in NB cells at 48 hr and 72 hr post salinomycin treatment. Intact NB cells were treated with 
salinomycin at indicated concentration or DMSO control for indicated periods of time and whole 
cell lysates were analyzed by Western blotting. β-actin served as a loading control. 
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5.2.2. Effect of salinomycin on the phosphorylation of TIF1β in NB cells 
It has been reported that p53 is required for the maintenance of the neuroblastic 
tumorigenic phenotype of NB and the down-regulation of p53 results in the conversion of N-type 
NB cells to the substrate-adherent fibroblast-like non-tumorigenic S-type NB cells [135]. 
Phosphorylated TIF1β is a critical regulator of cell proliferation and cell death through the 
degradation of p53 [151, 152]. Our results have shown that salinomycin down-regulates the 
expression of p53 (Figure 11). We then determine the phosphorylation of TIF1β in NB cells in 
response to salinomycin treatments. Our results revealed that salinomycin treatments induced 
phosphorylation of TIF1β at both S824 and S473 sites (Figure 22).  
 
Figure 22. Salinomycin induces TIF1β serine 473/824 phosphorylation. Immunoblots were 
probed with antibodies specific for TIF1β, TIF1β-phosphorylated (Ser473), TIF1β-
phosphorylated (S824), and reprobed with anti-β-actin antibody to serve as a loading control.  
 
5.2.3. The role of TIF1β on salinomycin’s regulation of p53 expression 
To further analyze the role of TIF1β on salinomycin’s regulation of p53 expression, we 
performed siRNA knockdown of TIF1β. As expected, in wild type cells, salinomycin treatment 
down-regulated p53 expression and up-regulated TIF1β phosphorylation. However, NB cells 
with knockdown of TIF1β did not show any further decrease in p53 expression upon 
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salinomycin treatment (Figure 23) suggesting salinomycin modulates p53 in a TIF1β dependent 
manner. 
 
 
Figure 23. Salinomycin induces TIF1β serine 473/824 phosphorylation and associated 
down-regulation of p53. (A) Knockdown of TIF1β reverts salinomycin’s effects on p53 
phosphorylation and expression. Immunoblots were probed with antibodies specific for TIF1β, 
TIF1β-phosphorylated (Ser473), TIF1β-phosphorylated (S824), or anti-p53, and reprobed with 
anti-β-actin antibody to serve as a loading control. (B) Quantification of the expression of p53 in 
SH-SY5Y cells under indicated treatment. 
 
5.2.4. Effects of salinomycin on the phosphorylation of NCL in NB cells 
We further determined the expression and phosphorylation of NCL in NB cells in 
response to salinomycin treatments and revealed that the expression and the phosphorylation of 
this molecule were both not significantly affected by salinomycin (Figure 24), suggesting that 
salinomycin mediates its anti-CSC effects by direct interactions with NCL, and unlikely to be 
involved in regulation of expression of NCL either transcriptionally or post-transcriptionally.   
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Figure 24. Expression levels of NCL and phosphor-NCL in NB cells upon salinomycin 
treatment. Intact NB cells were treated with 1 μM salinomycin or DMSO control for indicated 
periods of time and whole cell lysates were analyzed by Western blotting. β-actin served as a 
loading control. 
 
5.2.5. Effect of salinomycin on CD34 gene transcription 
NCL was previously shown to be recruited to CD34 promoter to direct CD34 gene 
transcription and regulate gene expression in CD34
+
 Hematopoietic cells [153, 154]. To 
determine how salinomycin regulates the expression of CD34, we analyzed the mRNA levels of 
CD34 in the three NB cell lines in response to salinomycin treatments. As expected, our data 
show that salinomycin significantly suppressed the mRNA expression of CD34 gene (P<0.01) 
(Figure 25). Among the three NB cell lines, the MYCN amplified IMR32 cell line has the 
highest level of CD34 mRNA, while the SK-N-AS non-tumorigenic cell line show the lowest 
expression of CD34 mRNA (Figure 25). 
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Figure 25. Salinomycin inhibits CD34 gene transcription. After treated with salinomycin or 
vehicle control for 24 hr, the expression of CD34 in NB cells was determined by reverse 
transcription-quantitative PCR and normalized using GAPDH as the internal control. *p<0.05 
and **p<0.01. 
 
5.2.6. Effect of salinomycin on CD34
+
 NB cells 
The expression of the hematopoietic stem cell (HSC) marker CD34 in NB cells and 
patients has been widely observed and considered as a confounding factor in the clinical 
management of NB [155, 156].  
To analyze whether the inhibition of salinomycin on CD34 transcription leads to the 
suppression on CD34
+
 NB cells, we further examined the effects of salinomycin on the CD34
+
 
population using flow cytometry.  Consistent with previous studies [155], we found the existence 
of CD34
+
 cell population in tumorigenic NB cells, while the non-tumorigenic SK-N-AS cell line 
show significant lower amount of CD34
+
 cells.  Intriguingly, upon 1 μM salinomycin treatment 
for 24 hr, the percentage of CD34
+
 cells was reduced from about 2.78% and 18.8% to 1.01% and 
8.53% for SH-SY5Y and IMR32 cells respectively (Figure 26). 
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Figure 26. Effect of salinomycin on CD34+ NB cells. (A) Salinomycin inhibits CD34+ cells. 
After treated with salinomycin or vehicle control for 24 hr, NB cells were stained with anti-
CD34 or IgG control and anti-mouse IgG-FITC and analyzed using flow cytometry. 
Representative results are shown. (B) Quantification of the flow cytometry data showing 
salinomycin inhibits CD34+ NB cells. **p<0.01. 
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5.2.7. The role of NCL on salinomycin’s regulation of CD34 transcription 
To determine how salinomycin regulates the expression of CD34, we examined the 
interaction of NCL with CD34 promoter using chromatin immunoprecipitation (ChIP) followed 
by quantitative PCR analysis in SH-SY5Y cells with or without treatment by salinomycin 
(Figure 27) [157].  
 
 
Figure 27. A schematic diagram of the CD34 cDNA and the site for ChIP analysis. Exons 
and introns are represented by boxes and curve lines respectively. The positions of the start and 
end base pair for each exon and the ChIP site are indicated by numbers. 
 
As shown in Figure 28, an antibody specifically recognizing the N-terminal peptide of 
NCL effectively co-precipitated CD34 promoter region from control. However, in salinomycin 
treated SH-SY5Y cell lysates, CD34 promoter-NCL complex was not observed. These data 
suggest that NCL directly interact with CD34 promoter and salinomycin treatment abolished the 
interaction between NCL and CD34 promoter in NB cells, and thereby disrupting NCL-mediated 
CD34 transcription. 
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Figure 28. ChIP-qPCR analysis of NCL-CD34 promoter interaction. SH-SY5Y cells treated 
with DMSO control or 1 μM salinomycin for 6 hr were subjected to ChIP-qPCR analysis.  
*p<0.05 and **p<0.01. 
 
5.2.8. Subcellular localization and expression of NCL and CD34 upon salinomycin 
treatment 
To examine the regulation of salinomycin on NCL and CD34, we first visualized the 
subcellular localization and expression of these two molecules in NB cells following exposure to 
salinomycin treatment. Our data show CD34 is predominantly expressed on the cell surface of 
SH-SY5Y cells, while NCL is mainly expressed in the nucleus (Figure 29). Alteration of the 
localization of NCL and CD34 in NB cells by salinomycin treatment was not observed. However, 
with increasing concentration of salinomycin treatment (0 μM, 0.25 μM, 0.5 μM, and 1 μM), the 
expression levels of cell surface CD34 molecule were apparently reduced (Figure 29). 
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Figure 29. Decreased CD34 protein expression following exposure to salinomycin 
treatment. SH-SY5Y cells were treated with salinomycin at indicated concentrations for 24 hr. 
Subcellular localization and expression of NCL and CD34 proteins were analyzed by 
immunofluorescent staining for endogenous CD34 labeled with anti-CD34 antibody (red), and 
NCL labeled with anti-NCL antibody (green) and examined by fluorescent microscopy. The 
nucleus was stained with Hoechst 33258 (blue). 
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5.2.9. The role of NCL on salinomycin’s regulation of CD34 protein expression 
To further understand the mechanism of NCL’s role in salinomycin’s regulation of CD34 
and CD34
+
 cells, we analyzed the role of NCL on CD34 protein expression with or without 
salinomycin treatment. As shown in Figure 30, salinomycin treatment did not significantly alter 
the levels of NCL, but slightly reduced the expression of CD34 protein.  
Overexpression of NCL by transient transfection of NCL plasmid induced a marked 
increase of CD34 protein expression, likely because of more NCL protein occupied the CD34 
gene promoters and activated CD34 expression. Intriguingly, upon salinomycin treatment, cells 
with overexpressed NCL showed more intensive response to salinomycin treatment in regard to 
the reduction in the protein expression levels of CD34, suggesting the disruption of the NCL-
CD34 promoter complex by salinomycin treatment (Figure 30 A-B). 
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Figure 30. NCL sensitizes salinomycin’s regulation on CD34 protein expression. (A) Cells 
incubated with GFP or GFP-NCL plasmids overnight were treated with DMSO control, 0.25 μM 
or 0.5 μM salinomycin. After 24 hr, whole cell lysates were analyzed by Western blotting. β-
actin served as a loading control. (B) Quantification of the protein expression levels. Level of 
statistical significance, compared GFP-NCL transfected cells with GFP transfected cells: 
#
p<0.05; compared GFP-NCL transfected cells with salinomycin treatment with GFP-NCL 
transfected cells with vehicle control treatment: ***p<0.001. 
 
In contrast, knockdown of NCL protein by using siRNAs decreased the expression levels 
of CD34 (Figure 31). We treated NCL knockdown NB cells with 0 μM, 0.25 μM, 0.5 μM, and 1 
μM salinomycin for 24 hr, however, these cells showed less response to salinomycin treatment 
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on the reduction in the protein expression levels of CD34 (Figure 30), suggesting salinomycin 
regulates CD34 in a NCL dependent manner. 
 
Figure 31. Knockdown of NCL down-regulates CD34 protein expression and salinomycin’s 
regulation on CD34 protein expression. (A) Cells incubated with control or NCL siRNAs for 
48 hr were treated with DMSO control, 0.25 μM, 0.5 μM, or 1 μM salinomycin. After 24 hr, 
whole cell lysates were analyzed by Western blotting. β-actin served as a loading control. (B) 
Quantification of the protein expression levels. Level of statistical significance, compared NCL 
siRNA transfected cells with respective control siRNA transfected cells: 
#
p<0.05 and 
**
p<0.01. 
 
5.2.10. The role of NCL on salinomycin’s regulation of CD34+ cells 
To further establish the functional link between NCL and CD34
+
 cells, we further 
analyzed the effects of NCL protein overexpression or knockdown on the percentage of CD34
+
 
cells in NB cells using flow cytometry. Our results show that knockdown of NCL slightly 
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reduced the percentage of CD34
+
 cells, and the effect was not further enhanced by salinomycin 
treatment (Figure 32).  
 
Figure 32. Effect of salinomycin on CD34
+
 NB cells in a NCL knockdown NB cells.  (A) 
Cells incubated with control or NCL siRNAs for 48 hr were treated with DMSO control or 0.25 
μM salinomycin. After 24 hr, cells were stained with anti-CD34-APC antibody or IgG control 
and were analyzed by flow cytometry. (B) Quantification of the flow cytometry data of Figure 
31A. Data represent the mean  SD of triplicate experiments. The statistical differences were 
determined using paired student’s t-test and performed using Minitab. *p<0.05. 
 
Notably, overexpression of NCL dramatically increased the percentage of CD34
+
 cells 
from about 4.64% to 17.2%. In the wild type or NCL overexpression NB cells, the inhibition of 
CD34
+
 cells by salinomycin were both observed (Figure 33). 
  
73 
 
 
Figure 33. Effect of salinomycin on CD34
+
 NB cells in a NCL overexpression NB cells.  (A) 
Cells incubated with GFP or GFP-NCL plasmids overnight were treated with DMSO control or 
0.25 μM salinomycin. After 24 hr, cells were stained with anti-CD34-APC antibody or IgG 
control and were analyzed by flow cytometry. (B) Quantification of the flow cytometry data of 
Fig. 7B. Data represent the mean  SD of triplicate experiments. The statistical differences were 
determined using paired student’s t-test and performed using Minitab. *p<0.05. 
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CHAPTER 6. SUMMARY, CLINICAL IMPLICATIONS, CONCLUSIONS, 
AND FUTURE DIRECTIONS 
6.1. Summary and discussions  
In this study, we demonstrated that salinomycin inhibits NB growth and tumorsphere 
formation and induces cell cycle arrest. By using chemoproteomics and anti-salinomycin affinity 
beads, we identified that NCL and TIF1β are salinomycin’s binding targets in NB cells. We 
further revealed that TIF1β and NCL play a critical role in salinomycin’s anti-cancer and anti-
CSC activity. We show that knockdown of NCL and/or TIF1β inhibits proliferation and 
tumorsphere formation while NB cells lacking NCL and TIF1β are no longer responding to 
salinomycin treatment. Our data also revealed that TIF1β is involved in salinomycin’s 
modulation of the p53 pathway, and NCL is required for salinomycin’s inhibition on the CSC 
marker CD34 gene transcription and CD34
+
 cell population.  
 
6.1.1. The effects of salinomycin in NB 
Our data showed the inhibitory effects of salinomycin on cell proliferation in the three 
NB cell lines at 48 h with IC50 values at 1μM for the N-type tumorigenic SH-SY5Y and IMR32 
cells, and > 4 μM for the S-type non-tumorigenic SK-N-AS cells, indicating salinomycin is more 
effective in tumorigenic cells. In addition, the IC50 value of salinomycin in N-type NB cells is 
much lower than some currently used chemotherapeutic drugs for NB, e.g. carboplatin, in the 
same in vitro cell line systems [158].  
Salinmycin induces cell cycle arrest at G2 phases and up-regulates cyclin A suggesting that up-
regulation of cyclin A level by salinomycin might be due to the prolonged G2 phases. In addition, 
p21 possesses an anti-apoptotic activity which allows for cell survival after exposure to DNA-
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damaging agents [159]. Our data show that salinomycin also decreased the p21 protein level in 
NB cells, suggesting that salinomycin may action in the attenuation of p21 and the subsequent 
subversion of the normal DNA-damage repair process. Our results are in agreement with 
previous reports that salinomycin could sensitize cancer cells to both radiation and 
chemotherapies by increasing DNA damage and reducing the increased p21 levels induced by 
radiation or chemotherapy [69, 70]. The cell cycle arrest at G2 phase and the up-regulation of 
cyclin A and down-regulation of the anti-apoptotic protein p21 and tumor suppressor p53 may 
contributes to salinomycin’s inhibition on NB cell proliferation.  
A complete inhibition of salinomycin on NB cell tumorsphere formation was also 
observed, which further demonstrated that salinomycin inhibits NB CSCs. Salinomycin also 
showed effective inhibition on CD133
+
 or c-kit
+
 CSC like NB cell population. CD133 is one of 
the most widely used markers for various somatic cells and putative CSCs, including NB CSCs 
[37, 38, 51]. Takenobu et al. reported that CD133 suppresses NB cell differentiation, but 
accelerates cell proliferation, colony formation, and in vivo tumor formation of NB cells [160]. 
Therefore, the down-regulation of NB cell proliferation and tumorsphere formation by 
salinomycin shown in our study is at least partially contributable to its inhibition on CD133
+
 NB 
cells. In addition, c-kit expression can be also detected in the majority of primary neuroblastic 
tumors including NB, and its expression is associated with unfavorable clinic-biological 
variables, such as MYCN [134]. Our study also showed that among the three tested NB cell lines, 
IMR32 cells with MYCN amplification contain higher percentage of c-kit
+
 cells. Functional 
blockade of c-kit receptors in NB cells was demonstrated to significantly decrease cellular 
growth rate [161], indicating the role of c-kit on the effects of salinomycin on NB cell 
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proliferation and cell cycle progression. Our study is the first to observe the profound anti-cancer 
and anti-CSC activities of salinomycin in human NB cells. 
 
6.1.2. Binding targets of salinomycin in NB 
In this study, we identified TIF1β and NCL as two binding targets of salinomycin in NB 
cells and both TIF1β and NCL are critical regulators of multiple cellular functions including cell 
proliferation, cell death and  maintenance of stem cell properties [136, 140, 162-166].  For 
instance, the functions of NCL span from ES cell self-renewal [136, 153] and NB cell 
differentiation [150]. In line with our findings, high levels of NCL signify tumorigenesis [140, 
167-171] while an absence of NCL induces cell growth arrest at G2 phase [149].  In this study, 
we observed that, knockdown of NCL inhibited cell proliferation by 30% and tumorsphere 
formation by 55% and salinomycin treatment could induce G2 cell cycle arrest. These results are 
consistent with previous reports that NCL is important for cell proliferation and tumorigenesis 
[172][140, 149, 167-171].  
Knockdown of TIF1β alone showed no significant effect on NB cell proliferation, but 
showed significant inhibition on tumorsphere formation, indicating a more important role for 
TIF1β in NB stem cell maintenance and cell differentiation compared to cell growth and 
proliferation control in NB cells. Cells knockdown both TIF1β and NCL no longer responded to 
salinomycin treatment on both cell proliferation and tumorsphere formation, indicating that 
TIF1β and NCL are functional cellular protein targets of salinomycin. The interaction of TIF1β 
and NCL in cancer cells may enhance tumor growth [138, 141].   
Previous studies have revealed the interaction between TIF1β and NCL in cancer cells. 
TIF1β and NCL were found to form complex with transcription-involved protein upregulated in 
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hepatocellular carcinoma (TIPUH1), which is associated with hepato-carcinogenesis, in 
hepatocellular carcinoma cells [141]. TIF1β also forms complex with NCL and ErbB4, and 
reduces ErbB4 transcription in breast cancer cells [138]. Our data also show co-IP of TIF1β and 
NCL in NB cells and positive correlation for the expression of TIF1β and NCL in NB patients. 
Future investigations on the functions of TIF1β and NCL and interactions between these proteins 
in NB are warranted. 
 
6.1.3. The mechanism of salinomycin in NB and the role of its binding targets  
Transplantation of autologous peripheral blood stem cells (PBSC), obtained by CD34
+
 
stem cell selection, permits intensified treatment for high risk NB patients [173]. However, the 
expression of the HSC marker CD34 on the surface of NB cell lines and tumors [155, 156] and 
the cancer relapse after autologous stem cell rescue caused by re-infused CD34 NB cells in NB 
patients [174] bring out the notion that CD34
+
 NB subpopulation may contain tumorigenic NB 
CSCs. Intriguingly, salinomycin binding target NCL mediates the activation of CD34 
transcription via binding to its promoter region [153]. In our study, by using ChIP-qPCR analysis, 
we show salinomycin efficiently reduce CD34
+
 cells and inhibit CD34 gene transcription by 
interfering with the binding of NCL with CD34 promoter region. In addition, the regulation of 
salinomycin on CD34 is highly NCL dependent. Future investigation on the molecular details of 
the interaction between CD34 and NCL in NB CSCs as well as HSCs will be valuable. More 
importantly, Lu and colleagues recently reported that in contrary to cancer cells, normal human 
peripheral blood lymphocytes show resistance to salinomycin toxicity [71]. Since our study 
showed marked inhibitory effects of salinomycin on CD34
+
 NB cells, salinomycin might be 
considered as a promising drug for high risk NB patients receiving high-dose 
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chemo/radiotherapy followed by autologous PBSC rescue in order to prevent cancer relapse and 
improve the survival after transplantation. Well-designed trials to address the effects of 
salinomycin on CD34
+
 NB cells as well as PBSCs will be valuable. 
It has been reported that p53 is required for the maintenance of the neuroblastic 
tumorigenic phenotype of NB and the down-regulation of p53 results in the conversion of N-type 
NB cells to the substrate-adherent fibroblast-like non-tumorigenic S-type NB cells [135]. 
Phosphorylated TIF1β is a critical regulator of cell proliferation and cell death through the 
degradation of p53 [151, 152]. We determined the protein expression and phosphorylation of 
TIF1β in NB cells in response to salinomycin treatments and revealed that salinomycin 
treatments did not alter the level of TIF1β total protein in NB cells but induced phosphorylation 
of TIF1β at both S824 and S473 sites and down-regulated the expression of p53. Interestingly, 
we observed two protein bands for p53 in the wild type SH-SY5Y and IMR32 cells but only one 
band for the SK-N-AS cells, suggesting there are different p53 splice variants [175, 176] in the 
tumorigenic and non-tumorigenic NB cell lines and different p53 isoforms may have distinct 
functions in NB, which would be valuable to study in the future. Level of cyclin A, which is 
known to regulate the G2/M transition in a p53 dependent manner [130, 131], was dramatically 
increased. Our data also show the inhibition of salinomycin on the p53 downstream target p21, a 
key regulator of cell cycle progression and the DNA damage response (DDR), which is in line 
with the findings that salinomycin is able to sensitize cancer cells to both radiation and 
chemotherapies by increasing DNA damage [69, 70]. Intriguingly, previous studies suggested 
that phosphorylation of TIF1β at both S824 and S473 sites are implicated in DDR [177, 178], 
and the phosphorylation of TIF1β at S473 in DDR was found to impact the G2/M checkpoint 
[178]. These results suggest the TIF1β-p53 axis may play an important role in salinomycin’t 
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effects on DDR. Moreover, NB cells with knockdown of TIF1β showed increased p53 
expression upon salinomycin treatment suggesting salinomycin modulates p53 in a TIF1β 
dependent manner. 
 
6.2. Clinical Implication 
Prognosis of NB could be very complex based on the disease stage, patient’s age, and 
highly heterogeneous tumor biology. Currently, some common prognostic factors, such as, 
patients’ age, MYCN amplification, deletion of parts of chromosome arm 1p and 11q, and gain 
of chromosome 17q, have been linked with unfavorable outcome.[29, 179-181] However, none 
of them can be used as an independent marker for NB prognosis, and searching for more 
meaningful biomarkers are needed.   
 
6.2.1. The correlation of TIF1β and NCL levels with NB patients’ outcomes 
To further analyze the clinical implication of TIF1β and NCL in NB, we queried the 
R2.amc.nl database for a comprehensive analysis and evaluation of the expression of TIF1β and 
NCL in a cohort of 498 NB patients and the correlation of the expression of TIF1β and NCL 
with patients’ outcomes. We found that an elevated level of TIF1β and NCL were associated 
with a significant risk of shortened survival (Figure 34 A-B) and an increased rate of relapse of 
the disease (Figure 34 C-D). 
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Figure 34. The expression of TIF1β and NCL in NB tumors and correlation of TIF1β and 
NCL levels with NB patients’ outcomes. (A) Kaplan-Meier plots of overall survival time 
according to TIF1β levels in NB patients. (B) Kaplan-Meier plots of overall survival time 
according to NCL levels in NB patients. (C) Kaplan-Meier plots of relapse free survival time 
according to TIF1β levels in NB patients. (D) Kaplan-Meier plots of relapse free survival time 
according to NCL levels in NB patients. 
 
6.2.2. The correlation of TIF1β and NCL levels with MYCN amplification 
Tumor stage and MYCN amplification are among the most highly statistically significant 
and clinically relevant risk factors for NB patients [179, 182]. It is noteworthy that in our 
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analysis, we found that the expression levels of TIF1β and NCL correlated with the tumor stage 
(Figure 35 A-B). Patients at stage 4 have markedly higher levels of both TIF1β and NCL 
compared with that of patients at stage 1. We have also found that the expression of TIF1β and 
NCL are correlated with the amplification of the oncogene MYCN (Figure 35 C-D) at diagnosis. 
This is also consistent with our in vitro study that IMR32 cells with MYCN amplification [183] 
express relatively higher levels of TIF1β and NCL than other cell lines and sensitive to 
salinomycin treatment. 
 
Figure 35. The correlation of TIF1β and NCL levels with poor prognostic markers. (A) The 
expression of TIF1β in NB patients diagnosed as INSS Stage 1 or Stage 4. (B) The expression of 
NCL in NB patients diagnosed as INSS Stage 1 or Stage 4. (C) The expression of TIF1β in NB 
patient with or without MYCN amplification. (D) The expression of NCL in NB patient with or 
without MYCN amplification. The band inside the box indicates the median value. The space 
between the upper and lower edge of the box represents the range of the data. The whisker 
represents the standard deviation.  
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6.2.3. The correlation of the expression levels between TIF1β and NCL 
Our data also show positive correlation for the expression of TIF1β and NCL in NB 
patients (Figure 36). 
 
Figure 36. The correlation of TIF1β and NCL levels in NB patients. Dot plot of TIF1β 
expression levels versus NCL expression levels in NB patients. Pearson’s correlation coefficient 
(r) and corresponding P value are displayed. 
 
6.3. Conclusions  
In summary, our work identify that NCL and TIF1β are salinomycin’s binding proteins in 
NB cells. Previous reports showed that both target proteins play important roles in multiple 
cellular functions including cell proliferation, cell death, and more importantly, the maintenance 
of stem cell properties [136, 140, 162-166], which may partially explain salinomycin’s 
preferential inhibition on CSC like cells. For instance, salinomycin suppresses the expression of 
CD34+ cells by disrupting the interaction of NCL binding to CD34 promoter, consequently 
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reducing the CSC-like population in NB cells. The proposed mechanism for the anti-cancer 
effects of salinomycin and the roles of its binding targets are shown in Figure 37. Furthermore, 
we revealed that salinomycin’s binding targets TIF1β and NCL are correlated with clinical 
outcomes of NB patients. Taken together, this study provides a therapeutic rationale for 
evaluating both salinomycin and TIF1β and NCL in NBs. 
 
Figure 37. Schematic representation of the interaction of salinomycin with its functional 
binding target proteins TIF1β and NCL in NB. 
 
6.4. Future directions 
Salinomycin was shown to induce terminal epithelial differentiation accompanied by cell-
cycle arrest rather than trigger cytotoxicity in breast cancer [88], and induce cell death and 
differentiation in head and neck squamous cell carcinoma stem cells despite activation of 
epithelial-mesenchymal transition and Akt [104]. The profound inhibitory effects of the CSC 
inhibitor salinomycin on NB cells and NB CSC like population shown by our data suggest the 
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impact of salinomycin on NB-CSCs. Interestingly, the salinomycin binding targets identified in 
our study, TIF1 and NCL, are both highly expressed in cancer cells and involved in stem cell 
maintenance and differentiation. TIF1 was identified as a self-renewal gene through a genome-
wide RNAi screen in mouse embryonic stem (ES) cells [162]. The depletion of TIF1 resulted in 
cell differentiation into the primitive endodermal lineage [164]. Similarly, NCL is required for 
the maintenance of embryonic stem cell self-renewal [136]. Therefore, for future investigations, 
to isolate NB-CSC population and determine the effects and mechanism of salinomycin and its 
binding targets on both NB-CSC subset and NB large population in respect to the stemness and 
cell differentiation will be valuable. 
Our study for the first time demonstrated the anti-cancer effects of salinomycin in NB in 
vitro. However, the effects and mechanism of salinomycin and the role of its binding targets in 
NB in vivo models have not been investigated yet. In our future investigation, we would extend 
our study to examine the mechanism of salinomycin in NB mice models established by using 
wild type NB cell lines, TIF1 and/or NCL knockdown NB cells, as well as the isolated NB CSC 
like populations. Noteworthy, the tumorigenicity of CD34
+
 NB cells in mice model has not been 
studied up to the present. Using the in vivo mice models, we anticipate our study revealing 
important information in NB and the understanding of salinomycin’s mechanism of action.  
In our study, we have identified TIF1 and NCL as potential salinomycin’s binding 
targets in NB cells using a modified drug affinity based proteolytic enzyme digestion analysis 
[124, 184].  With the aid of structural modeling (data not shown), we predict that salinomycin 
may bind to TIF1 and NCL at their DNA binding domain and RNA binding domain 
respectively. To further understand the interaction between salinomycin and its binding targets, 
we would evaluate our in silicon models to determine the binding affinities and to identify the 
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binding sites of TIF1 and NCL with salinomycin by performing crystallization using wild type 
and mutant TIF1 and NCL proteins with salinomycin.  
As illustrated in Figure 5, previous studies have revealed a few possible mechanisms for 
salinomycin’s anti-cancer activity, for instance, the activation of unconventional pathways of cell 
death, enhanced DNA damage, and the inhibition of Wnt signaling pathway, appear to be 
germane to the multi-dimensional anti-CSC and anti-tumorigenic activities of salinomycin [66-
71]. The relationship of our discovered TIF1 and NCL related mechanism with these existing 
mechanisms remains unclear. As discussed earlier, previous studies and our data have shown the 
induction of salinomycin in DDR [69, 70]. The phosphorylation of TIF1β at both S824 and S473 
sites and its associated regulation of p53 were also implicated in DDR [177, 178]. These results 
suggest the TIF1β-p53 axis may play an important role in salinomycin’t effects on DDR. Future 
investigation on the role of TIF1β on salinomycin’s effect on DDR is warranted. The mechanism 
of salinomycin in CSCs has been linked to its inhibitory effects in Wnt signaling by blocking the 
phosphorylation of the Wnt co-receptor lipoprotein receptor related protein 6 (LRP6) and 
inducing its degradation [71] or by suppressing LRP6 expression and subsequently inhibits 
Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells [185]. Salinomycin has 
also been shown to inhibit gastric tumor growth by suppressing Wnt signaling in CSCs [186]. 
Interestingly, salinomycin’s binding target NCL is also closely associated with Wnt signaling. 
Cell surface NCL was found to exist in a highly stable 500-KDa protein complex including two 
Wnt related proteins, and targeting surface NCL could change the organization of the complex 
and thus lead to inhibitory effects of cancer cells [187]. In addition, NCL was also found to be a 
binding partner with urokinase-type plasminogen activator (uPA) which is overexpressed in the 
tumor-stromal invasive microenvironment in many human cancers [188], and plays a vital role in 
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cancer stemness [189]. Notably, the receptor (i.e, uPA receptor [uPAR]) for this NCL binding 
partner has been shown to regulate Wnt/β-catenin signaling and mediate induction of CSC-like 
population in medulloblastoma cells [190]. These studies suggest NCL may be involved in 
salinomycin’s regulation in Wnt signaling. Further investigations are required on the function of 
NCL in the regulation of Wnt signaling. 
By analyzing the expression levels of TIF1β and NCL in 498 NB samples of R2 database, 
we revealed that elevated levels of TIF1β and NCL in NB are associated with a poor outcome. In 
this study, we found that the expression levels of salinomycin target proteins, TIF1β and NCL, 
are correlated with NB patient survival and disease relapse very well, and both of them are 
possible new prognostic factors for NB prognosis. Future clinical studies with larger number of 
patients will be valuable for further evaluation of the prognostic values of these new markers. 
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